var title_f22_1_22544="Lymphoma testis ultrasound";
var content_f22_1_22544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphoma of testis on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound examination of the right testis demonstrates a large anechoic mass lesion occupying most of the testis. The edges of the testis are outlined with arrows.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22544=[""].join("\n");
var outline_f22_1_22544=null;
var title_f22_1_22545="Fissured tongue 2";
var content_f22_1_22545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fissured tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22545=[""].join("\n");
var outline_f22_1_22545=null;
var title_f22_1_22546="Erythema gyratum repens 2";
var content_f22_1_22546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema gyratum repens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple concentric erythematous plaques are present in this patient with erythema gyratum repens.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22546=[""].join("\n");
var outline_f22_1_22546=null;
var title_f22_1_22547="Nesiritide: Patient drug information";
var content_f22_1_22547=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nesiritide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     see \"Nesiritide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Natrecor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nesiritide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703784",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11225 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22547=[""].join("\n");
var outline_f22_1_22547=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200829\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013505\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013504\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013508\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013509\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013511\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013507\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013513\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=related_link\">",
"      Nesiritide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_1_22548="Sevelamer: Patient drug information";
var content_f22_1_22548=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sevelamer: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     see \"Sevelamer: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23684?source=see_link\">",
"     see \"Sevelamer: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Renagel&reg;;",
"     </li>",
"     <li>",
"      Renvela&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Renagel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high phosphate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sevelamer or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble swallowing, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696897",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take other drugs within 3 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix the",
"       <b>",
"        0.8 g",
"       </b>",
"       packet contents with 2 tablespoons (30 mL) of water or the",
"       <b>",
"        2.4 g",
"       </b>",
"       packet contents with 4 tablespoons (60 mL) of water. Stir and drink within 30 minutes. Powder will not melt.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11045 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22548=[""].join("\n");
var outline_f22_1_22548=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220777\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220778\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023494\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023493\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023498\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023499\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023501\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023496\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023497\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023502\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023503\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=related_link\">",
"      Sevelamer: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23684?source=related_link\">",
"      Sevelamer: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_1_22549="Poison ivy 1";
var content_f22_1_22549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Poison ivy leaves and flowers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Green or green-reddish leaves grow in groups of three and have smooth, fine-toothed, or lobed margins, and small, yellow-green flowers form cream-colored fruit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22549=[""].join("\n");
var outline_f22_1_22549=null;
var title_f22_1_22550="Valsartan: Pediatric drug information";
var content_f22_1_22550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Valsartan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"    see \"Valsartan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/15/21749?source=see_link\">",
"    see \"Valsartan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diovan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Valsartan;",
"     </li>",
"     <li>",
"      Diovan&reg;;",
"     </li>",
"     <li>",
"      Ran-Valsartan;",
"     </li>",
"     <li>",
"      Sandoz-Valsartan;",
"     </li>",
"     <li>",
"      Teva-Valsartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1041931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin II Receptor Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1041966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"      see \"Valsartan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypertension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-5 years: Not recommended for use due to possible safety issues; one study (n=90; mean age: 3.2 years; minimum patient weight: 8 kg) randomized patients to receive low, medium, or high doses according to patient body weight. Patients &lt;18 kg received low dose: 5 mg once daily; medium dose: 20 mg once daily; or high dose: 40 mg once daily. Patients &ge; 18 kg received low dose: 10 mg once daily; medium dose: 40 mg once daily; or high dose: 80 mg once daily. These set doses resulted in a mean dosage of 0.4-3.4 mg/kg once daily (Flynn, 2008). Although some efficacy was demonstrated, two deaths and three cases of increased liver enzymes occurred. Even though patients had significant comorbidities and a causal relationship to valsartan could not be established, a relationship to treatment with valsartan could not be excluded. Thus, use in children &lt;6 years of age is not recommended by the manufacturer (Diovan&reg; package insert, 2007). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-16 years: Manufacturer&rsquo;s recommendations: Initial: 1.3 mg/kg once daily (maximum: 40 mg/day); dose may be increased to achieve desired effect; doses &gt;2.7 mg/kg (maximum: 160 mg) have not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to increased bioavailability of oral suspension, patient may require a higher dose when replacing oral suspension with tablet dosage form.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Initial: 80 mg or 160 mg once daily (in patients who are not volume depleted); dose may be increased to achieve desired effect; maximum recommended dose: 320 mg once daily; usual dosage range (JNC 7): 80-320 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heart failure: Adults: Initial: 40 mg twice daily; titrate dose to 80-160 mg twice daily, as tolerated; maximum dose: 320 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Use is not recommended if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: No dosage adjustment necessary if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;10 mL/minute; use with caution in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     In mild-to-moderate liver disease, no adjustment is needed. Use caution in patients with liver disease. Patients with mild-to-moderate chronic liver disease have twice the exposure as healthy volunteers.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diovan&reg;: 40 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diovan&reg;: 80 mg, 160 mg, 320 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1041972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1041953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature at 25&deg;C (77&deg;F). Protect from moisture; dispense in tightly closed container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1041932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of essential hypertension alone or in combination with other antihypertensive agents (FDA approved in ages 6-16 years and adults); reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction postmyocardial infarction (FDA approved in adults); treatment of heart failure (NYHA Class II-IV) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Valsartan may be confused with losartan, Valstar&reg;, Valturna&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diovan&reg; may be confused with Zyban&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Diovan [U.S., Canada, and  multiple international markets] may be confused with Dianben, a brand name for metformin [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F233230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, orthostatic hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache, postural dizziness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Serum potassium increased, hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (including upper), diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Vertigo",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      All indications:",
"     </b>",
"     Rare but important or life-threatening: Allergic reactions, alopecia, anaphylaxis, anemia, angioedema, anorexia, anxiety, chest pain, constipation, dyspepsia, dyspnea, flatulence, hematocrit/hemoglobin decreased, hepatitis (rare), impotence, insomnia, liver function tests increased, microcytic anemia, muscle cramps, myalgia, palpitation, paresthesia, photosensitivity, pruritus, rash, renal failure, rhabdomyolysis, somnolence, taste disorder, thrombocytopenia (very rare), vasculitis, vomiting, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1041937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to valsartan, any component, or other angiotensin II receptor blockers",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6854352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment (clearance of valsartan is reduced in these patients). Use with caution in patients with impaired renal function; use is associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure); deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation in patients with progressive and/or significant deterioration in renal function. Hyperkalemia may occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts; use with caution in these patients and with these agents; monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Symptomatic hypotension may occur, especially in patients with an activated renin-angiotensin system (eg, volume- or salt-depleted patients receiving high doses of diuretic agents); use with caution in these patients; correct depletion before starting therapy or initiate therapy under close medical supervision. Use with caution in patients with heart failure or post-MI (symptomatic hypotension may occur). Not recommended for use in children &lt;6 years of age due to possible safety issues; not recommended for use in children with GFR &lt;30 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     (no data exists)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1041938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus when used during pregnancy. ARBs should be discontinued as soon as possible once pregnancy is detected",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Neonatal hypotension, skull hypoplasia, anuria, renal failure, oligohydramnios (associated with fetal limb contractures, craniofacial deformities, hypoplastic lung development), prematurity, intrauterine growth retardation, patent ductus arteriosus, and death have been reported with the use of ACE inhibitors, primarily in the second and third trimesters. Concomitant use of an ACE inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F233218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of SLCO1B1;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide: May enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1041952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Food decreases the peak plasma concentration and extent of absorption by 50% and 40%, respectively. Limit salt substitutes or potassium-rich diet. Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1041974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, BUN, serum creatinine, renal function, baseline and periodic serum electrolytes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1041955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Valsartan produces direct antagonism of the effects of angiotensin II. Unlike the ACE inhibitors, valsartan blocks the binding of angiotensin II to the AT1 receptor subtype. It produces its blood pressure-lowering effects by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. This action results in more efficient blockade of the cardiovascular effects of angiotensin II and fewer side effects than the ACE inhibitors. Valsartan does not affect the ACE (kininase II) or the response to bradykinin.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F6854357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensive effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Onset of action: 2 hours postdose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maximum effect: Within 6 hours postdose; with chronic dosing, substantial hypotensive effects are seen within 2 weeks; maximum effect: After 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duration: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1041957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : 17 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%, primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To inactive metabolite (valeryl 4-hydroxy valsartan) via unidentified enzyme(s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 25% (range: 10% to 35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: ~40% (~1.6 times more than tablet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: Adults: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Tablets (Adults): 2-4 hours; Suspension (Children): 2 hours (Blumer, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted in feces (83%) and urine (13%) primarily as unchanged drug; 20% of dose is recovered as metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Found to be similar per kg bodyweight in children vs adults receiving a single dose of the suspension (Blumer, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1041978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/15/21749?source=see_link\">",
"      see \"Valsartan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by prescriber (especially sleep remedies or antisleep products, cough or cold remedies, or weight-loss products). Take exactly as directed and do not discontinue without consulting prescriber. This drug does not eliminate need for diet or exercise regimen as recommended by prescriber. May cause dizziness or lightheadedness (use caution when driving or engaging in tasks that require alertness until response to drug is known); postural hypotension (use caution when rising from lying or sitting position or climbing stairs); or diarrhea. Report changes in urinary pattern; swelling of extremities; unusual back ache; chest pain or palpitations; unrelenting headache; muscle weakness or pain; unusual cough; or other persistent adverse reactions. This medication may cause injury and death to the developing fetus when used during pregnancy; women of childbearing potential should be informed of potential risk; consult prescriber for appropriate contraceptive measures; this medication should be discontinued as soon as possible once pregnancy is detected.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F5605993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 4 mg/mL oral suspension may be made from tablets, Ora-Plus&reg;, and Ora-Sweet&reg; SF. Add 80 mL of Ora-Plus&reg; to an 8-ounce amber glass bottle containing eight valsartan 80 mg tablets. Shake well for &ge;2 minutes. Allow the suspension to stand for a minimum of 1 hour, then shake for &ge;1 minute. Add 80 mL of Ora-Sweet SF&reg; to the bottle and shake for &ge;10 seconds. Store in amber glass prescription bottles; label \"shake well\". Stable for 30 days at room temperature or 75 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Diovan&reg; prescribing information, Novartis Pharmaceuticals Corp, East Hanover, NJ, 2012.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Blumer J, Batisky DL, Wells T, et al, \"Pharmacokinetics of Valsartan in Pediatric and Adolescent Subjects With Hypertension,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2009, 49(2):235-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/1/22550/abstract-text/19179299/pubmed\" id=\"19179299\" target=\"_blank\">",
"        19179299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT, Meyers KE, Neto JP, et al, \"Efficacy and Safety of the Angiotensin Receptor Blocker Valsartan in Children With Hypertension Aged 1 to 5 Years,\"",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2008, 52(2):222-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/1/22550/abstract-text/18591457/pubmed\" id=\"18591457\" target=\"_blank\">",
"        18591457",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13078 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22550=[""].join("\n");
var outline_f22_1_22550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708863\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233186\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233187\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041931\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041966\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233160\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233145\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041972\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041953\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041932\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233232\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233230\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041937\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6854352\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041938\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233218\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233154\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041952\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233156\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233170\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041974\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041955\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6854357\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041957\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041978\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605993\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13078\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13078|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=related_link\">",
"      Valsartan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/15/21749?source=related_link\">",
"      Valsartan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_1_22551="Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)";
var content_f22_1_22551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/1/22551/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22551/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22551/contributors\">",
"     Nelson Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22551/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/1/22551/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22551/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/1/22551/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22551/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/1/22551/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term myeloma kidney or myeloma cast nephropathy refers to a disorder in which monoclonal urinary immunoglobulin light chains (Bence Jones proteins) lead to acute or chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    .) Light chains have a molecular weight of approximately 22,000. They are freely filtered across the glomerulus and then largely reabsorbed by the proximal tubular cells. The normal rate of light chain excretion is less than 30",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    However, reabsorptive capacity can be exceeded due to overproduction in multiple myeloma, resulting in an increase in light chain excretion that can range from 100 mg to more than 20",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p>",
"    Light",
"    chains are usually not detected by the urinary dipstick, which primarily senses albumin. Thus, the urine should be tested with sulfosalicylic acid (SSA, which detects all proteins) in any patient with acute or chronic renal failure, a bland urine sediment, and a negative or trace-positive dipstick. A markedly positive SSA test (as detected by the degree of turbidity when SSA is added to the urine) with a relatively negative dipstick is strongly suggestive of the presence of non-albumin proteins, such as light chains.",
"   </p>",
"   <p>",
"    This topic provides a review of the pathogenesis and diagnosis of myeloma cast nephropathy. Overviews of the renal diseases associated with multiple myeloma and the therapy of acute renal failure in multiple myeloma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=see_link\">",
"     \"Treatment of kidney disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cast nephropathy occurs in the presence of excess free light chains in the plasma and urine. Cast nephropathy is rare in patients with low serum free light chain concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/3\">",
"     3",
"    </a>",
"    ]. On the other hand, renal impairment is 24- to 27-fold higher in patients with high urinary immunoglobulin light chain excretion especially patients with &gt;12",
"    <span class=\"nowrap\">",
"     g/g",
"    </span>",
"    creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/4\">",
"     4",
"    </a>",
"    ]. The mechanism by which urinary light chains lead to renal failure is incompletely understood. Two factors are likely to be of primary importance: intratubular cast formation and direct tubular toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/2\">",
"     2",
"    </a>",
"    ]. Light chains can precipitate in the tubules as a result of binding with Tamm-Horsfall mucoprotein (THMP, also called uromodulin), which is a protein of uncertain function that is normally secreted by cells of the thick ascending limb of the loop of Henle and that constitutes the matrix of all urinary casts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The binding and precipitation leads to the formation of obstructing, dense, intratubular casts in the distal and collecting tubules that may initiate a giant cell reaction (",
"    <a class=\"graphic graphic_picture graphicRef57572 graphicRef70405 graphicRef82327 \" href=\"UTD.htm?16/0/16394\">",
"     picture 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The obstructing casts cause tubular rupture which allows extravasation of monoclonal light chain into the interstitium. Studies found that monoclonal immunoglobulin light chains are capable of activating nuclear factor-&kappa;B (NF&kappa;B) via Src kinases particularly c-Src [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/9\">",
"     9",
"    </a>",
"    ]. The inflammation seen in myeloma cast nephropathy is the result of activation of chemokines such as monocyte chemotactic protein-1 (MCP-1) via this mechanism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9378?source=see_link\">",
"     \"Chapter 4D: Tamm-Horsfall mucoprotein\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important contributor to cast nephropathy is volume depletion, which may promote cast formation by slowing flow within the tubules and by promoting the formation of large aggregates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/2,5,10\">",
"     2,5,10",
"    </a>",
"    ]. Other factors that have been postulated to promote intratubular cast formation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loop diuretics, by increasing luminal sodium chloride (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Role of tubular injury'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Increased urinary calcium as a result of hypercalcemia, a common finding in multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/2,11\">",
"       2,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiocontrast media, which may interact with light chains and promote intratubular obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs, which may precipitate the acute kidney injury in 7 to 18 percent of affected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Risk of acute kidney injury associated with these drugs is highest in patients with Bence-Jones proteinuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role of tubular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cast formation is relatively minor in some patients in whom the degree of renal failure correlates best with tubular damage and atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. Tubular injury, at least in the proximal tubule, presumably results from the reabsorption of some of the filtered light chains into the tubular cell. Their accumulation within the cell may then interfere with lysosomal function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tubular injury can promote the development of renal failure, at least in part by enhancing cast formation. As an example, proximal tubular dysfunction can decrease further proximal light chain reabsorption, thereby increasing delivery to the distal nephron where cast formation can occur. Light chains can also interfere with tubular function in the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/8\">",
"     8",
"    </a>",
"    ]. The ensuing increase in tubular fluid sodium chloride concentration (since less is being reabsorbed) can also promote cast formation by increasing the aggregation of light chains with locally released Tamm-Horsfall mucoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/5,6,8\">",
"     5,6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal studies in which nephrotoxic human light chains are perfused into the rat nephron suggest that a loop diuretic (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ) can enhance cast formation by the same mechanism: an elevation in the luminal sodium chloride concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/5\">",
"     5",
"    </a>",
"    ]. This may be important clinically, since loop diuretics are often given empirically (and perhaps deleteriously) to patients with myeloma cast nephropathy in an attempt to wash out obstructing casts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Light chain characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with myeloma cast nephropathy generally excrete more than 1 g of light chains per day [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/1\">",
"     1",
"    </a>",
"    ]. However, much larger quantities are occasionally excreted without any substantial change in renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. This observation indicates that different light chains have a variable nephrotoxic potential, a finding that has been confirmed in experimental models [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/2,5,6,8,17,19,20\">",
"     2,5,6,8,17,19,20",
"    </a>",
"    ]. Much of the nephrotoxicity is dependent on the affinity of the light chain toward THMP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cast nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental studies suggest that one important determinant of the potential of a particular light chain to form intratubular casts is the affinity of its binding to THMP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. A specific binding site for immunoglobulin light chains has been identified on THMP; this site consists of a linear sequence of nine amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/6\">",
"     6",
"    </a>",
"    ]. This nine amino acid segment binds to the complementary determining region 3 (CDR3) of immunoglobulin light chains. Light chains with high affinity appear to be more likely to produce obstructing intratubular casts. However, light chains with only moderate affinity for THMP may still induce cast formation if tubular concentration is increased by high serum concentration or hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/6\">",
"     6",
"    </a>",
"    ]. A competitive inhibitor peptide that prevents binding of light chains to THMP decreases intratubular cast formation and prevents acute kidney injury in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another contributing factor to THMP binding and the predisposition to cast nephropathy may be the isoelectric point (pI) of the light chain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/2,8,12\">",
"     2,8,12",
"    </a>",
"    ]. Bence Jones proteins with a pI above 5.1 (that is, above the tubular fluid pH in the distal nephron) will have a net positive charge, a characteristic that may promote binding via charge interaction to anionic THMP (pI = 3.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/5,12,17\">",
"     5,12,17",
"    </a>",
"    ]. Urinary alkalinization might be beneficial by reducing binding of the light chain to THMP by causing the light chains to become less cationic or even anionic, and by changing the charge on a single histidine residue in the binding site of Tamm-Horsfall mucoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/6,12,17\">",
"     6,12,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another determinant of ability of the light chain to cause renal disease may be its tendency to form high molecular weight aggregates that are more likely to form casts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/10\">",
"     10",
"    </a>",
"    ]. In comparison, light chains from patients without renal disease generally do not form these aggregates. A high urine volume may also prevent aggregation and cast formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, it is important for the patient to drink enough fluid to produce three liters of urine daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Amyloid deposits and LCDD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different factors appear to predispose to the formation of amyloid deposits. Certain amino acids at specific sites on the light chain may facilitate protein unfolding, thereby increasing the likelihood of forming tissue aggregates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .) This property is determined at the level of the amino acid sequence. Experiments infusing light chains from individual patients into mice produce the same form of renal disease (cast nephropathy, amyloid deposition, or lack of disease) as seen in the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Renal tubular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with multiple myeloma develop signs of tubular dysfunction without renal failure. The proximal tubule is primarily affected, resulting in abnormalities such as renal tubular acidosis, hypouricemia, hypophosphatemia, and aminoaciduria due to renal phosphate wasting (eg, Fanconi syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The light chains that produce this lesion are resistant to degradation by proteases in tubular cell lysosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/23\">",
"     23",
"    </a>",
"    ]. Accumulation of the variable domain fragments, with subsequent intracellular crystal formation, is presumably responsible for the impairment in tubular function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/19,24\">",
"     19,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other associated diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased light chain excretion and renal failure can rarely occur in conditions other than multiple myeloma. This has been described with monoclonal light chains in lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/25\">",
"     25",
"    </a>",
"    ], Waldenstr&ouml;m&rsquo;s macroglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/26\">",
"     26",
"    </a>",
"    ], and with polyclonal light chains, due to proximal tubular damage induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Interleukin-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-6 (IL-6) is an important growth factor for plasma cells in multiple myeloma. This process may be enhanced in bone where myeloma cells may upregulate IL-6 production by osteoblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/28\">",
"     28",
"    </a>",
"    ]. IL-6 is also secreted by stromal cells in marrow.",
"   </p>",
"   <p>",
"    Experimental studies suggest that IL-6 plays a role in the pathogenesis of myeloma cast nephropathy. Some transgenic mice with an extra IL-6 gene develop a polyclonal gammopathy and acute renal failure with cast nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/29\">",
"     29",
"    </a>",
"    ]. How this occurs is incompletely understood, since renal failure is not seen in other models with polyclonal gammopathy. One possible contributory factor is stimulation of hepatic release of acute phase reactants by IL-6; these proteins may directly promote cast formation or act indirectly by impairing light chain reabsorption.",
"   </p>",
"   <p>",
"    IL-6 also may contribute to the development of hypercalcemia in multiple myeloma and other malignancies, in part by direct stimulation of osteoclast function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     NF-kappaB and MAPKs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to IL-6, increased production of other inflammatory cytokines including interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) has been demonstrated with exposure of proximal tubular cells to myeloma light chains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/30\">",
"     30",
"    </a>",
"    ]. This increased production of the cytokines is mediated through transcription factors, such as NF-kappaB and mitogen activated protein kinases (MAPKs) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Among the MAPKs, ERK",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    appears to play the dominate role, but JNK",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    and p38 also contribute. Supporting evidence comes from experiments in which inhibition of the individual MAPKs blocks the increased production of the inflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of myeloma cast nephropathy should be suspected in any patient over age 40 who presents with otherwise unexplained acute or subacute renal failure. A significant proportion of patients will not have a previously diagnosed multiple myeloma or other monoclonal gammopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/14,33\">",
"     14,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential contributors to acute renal failure should be explored and addressed if present, such as volume depletion and hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=see_link\">",
"     \"Treatment of kidney disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urine dipstick is negative or only trace positive for protein, and the sediment is typically bland. Light chains are usually not detected by the urinary dipstick, which primarily senses albumin. In contrast, patients with amyloidosis or light chain deposition disease typically present with nephrotic syndrome, including heavy proteinuria, hypoalbuminemia, and edema, with a urine dipstick unequivocally positive for protein. This was demonstrated in a review of 260 patients with known multiple myeloma and biopsy-demonstrated kidney lesions including amyloidosis (n = 177), cast nephropathy (n = 43), light chain deposition disease (n = 28) and acute tubular necrosis (n = 12) (",
"    <a class=\"graphic graphic_figure graphicRef87690 \" href=\"UTD.htm?29/31/30206\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/34\">",
"     34",
"    </a>",
"    ]. The percentage urinary albumin excretion, calculated from the urine protein electrophoresis, was lower among patients with contrast nephropathy compared with acute tubular necrosis, light chain deposition disease and amyloidosis (7 versus 25, 55, and 70 percent, respectively). Using a cut-off of 25 percent, the urinary albumin excretion ratio had a positive predictive value of 0.75 and a negative predictive value of 0.99 percent. In this study, no patient with cast nephropathy had a urinary albumin excretion &gt;26 percent.",
"   </p>",
"   <p>",
"    In the rare cases that myeloma cast nephropathy is present concurrently with light chain deposition disease or amyloidosis, the clinical features are usually determined by the glomerular disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/14,35,36\">",
"     14,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the urine in any patient with acute or chronic renal failure, a bland urine sediment, and a negative or trace-positive dipstick should be tested with sulfosalicylic acid (SSA), which detects all proteins. A markedly positive SSA test (as detected by the degree of turbidity when SSA is added to the urine) with a relatively negative dipstick is highly suggestive of the presence of non-albumin proteins, such as light chains (Bence Jones protein).",
"   </p>",
"   <p>",
"    Serum protein electrophoresis, immunofixation, and free light chain assay should be obtained on every patient. A 24-hour urine collection and serum should be sent for protein electrophoresis and immunofixation to confirm the identity of the monoclonal protein and determine the amount of monoclonal light chain and albuminuria. Quantitative interpretation of the results is unreliable when the glomerular filtration rate is reduced, since the urinary excretion of monoclonal free light chains decreases with declining glomerular filtration rate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .) However, the free light chain ratio (defined as the ratio of the involved light chain to the uninvolved light chain) may distinguish cast nephropathy from other lesions associated with myeloma. In the study cited above, patients with cast nephropathy had much higher ratios compared with patients with either amyloidosis or light chain deposition disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the light chain ratio did not distinguish cast nephropathy from acute tubular necrosis. A low urine albumin excretion especially &lt;10 percent is highly suggestive of myeloma cast nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22551/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is usually made based on suggestive clinical features and the presence of elevated quantities of monoclonal free light chains in both the serum and urine. However, a definitive diagnosis requires a kidney biopsy. A kidney biopsy is also recommended when the history or clinical features are atypical for myeloma cast nephropathy (eg, significant proteinuria suggesting amyloid or LCDD, or an active urinary sediment suggesting acute tubular necrosis, interstitial nephritis, or glomerulonephritis) or when a drug history suggests allergic interstitial nephritis. It is important to differentiate these entities so that proper treatment can be undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Light chain cast nephropathy most often occurs with multiple myeloma but has been described rarely in other conditions.",
"     </li>",
"     <li>",
"      The most important factors that promote the development of myeloma cast nephropathy are a high rate of light chain excretion, the biochemical characteristics of the light chain, and concurrent volume depletion. Hypercalcemia, which is a common finding in multiple myeloma, may also contribute.",
"     </li>",
"     <li>",
"      The diagnosis must be suspected in the older patient presenting with acute or subacute renal failure, particularly if the urine dipstick is negative for protein, whether or not the patient has a previously diagnosed multiple myeloma or monoclonal gammopathy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis can only be made definitively with a kidney biopsy. However, the diagnosis is often established in cases of multiple myeloma with acute renal failure by identifying the presence of large amounts of monoclonal free light chains in the serum and the presence of monoclonal light chains in the urine by protein electrophoresis and immunofixation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"       \"Recognition of monoclonal proteins\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/1\">",
"      DeFronzo RA, Cooke CR, Wright JR, Humphrey RL. Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978; 57:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/2\">",
"      Sanders PW. Pathogenesis and treatment of myeloma kidney. J Lab Clin Med 1994; 124:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/3\">",
"      Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011; 22:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/4\">",
"      Drayson M, Begum G, Basu S, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood 2006; 108:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/5\">",
"      Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992; 89:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/6\">",
"      Huang ZQ, Sanders PW. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest 1997; 99:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/7\">",
"      Pirani CL, Silva F, D'Agati V, et al. Renal lesions in plasma cell dyscrasias: ultrastructural observations. Am J Kidney Dis 1987; 10:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/8\">",
"      Sanders PW, Booker BB, Bishop JB, Cheung HC. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 1990; 85:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/9\">",
"      Ying WZ, Wang PX, Aaron KJ, et al. Immunoglobulin light chains activate nuclear factor-&kappa;B in renal epithelial cells through a Src-dependent mechanism. Blood 2011; 117:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/10\">",
"      Myatt EA, Westholm FA, Weiss DT, et al. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci U S A 1994; 91:3034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/11\">",
"      Smolens P, Barnes JL, Kreisberg R. Hypercalcemia can potentiate the nephrotoxicity of Bence Jones proteins. J Lab Clin Med 1987; 110:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/12\">",
"      Holland MD, Galla JH, Sanders PW, Luke RG. Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney Int 1985; 27:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/13\">",
"      Morgan C Jr, Hammack WJ. Intravenous urography in multiple myeloma. N Engl J Med 1966; 275:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/14\">",
"      Sakhuja V, Jha V, Varma S, et al. Renal involvement in multiple myeloma: a 10-year study. Ren Fail 2000; 22:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/15\">",
"      Magee C, Vella JP, Tormey WP, Walshe JJ. Multiple myeloma and renal failure: one center's experience. Ren Fail 1998; 20:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/16\">",
"      Sanders PW, Herrera GA, Lott RL, Galla JH. Morphologic alterations of the proximal tubules in light chain-related renal disease. Kidney Int 1988; 33:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/17\">",
"      Sanders PW, Herrera GA, Chen A, et al. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest 1988; 82:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/18\">",
"      Kyle RA, Greipp PR. \"Idiopathic\" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med 1982; 306:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/19\">",
"      Decourt C, Rocca A, Bridoux F, et al. Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. Blood 1999; 94:3559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/20\">",
"      Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/21\">",
"      Ying WZ, Allen CE, Curtis LM, et al. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. J Clin Invest 2012; 122:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/22\">",
"      Ma CX, Lacy MQ, Rompala JF, et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 2004; 104:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/23\">",
"      Leboulleux M, Lelongt B, Mougenot B, et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int 1995; 48:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/24\">",
"      Lajoie G, Leung R, Bargman JM. Clinical, biochemical, and pathological features in a patient with plasma cell dyscrasia and Fanconi syndrome. Ultrastruct Pathol 2000; 24:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/25\">",
"      Burke JR Jr, Flis R, Lasker N, Simenhoff M. Malignant lymphoma with \"myeloma kidney\" acute renal failure. Am J Med 1976; 60:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/26\">",
"      Isaac J, Herrera GA. Cast nephropathy in a case of Waldenstr&ouml;m's macroglobulinemia. Nephron 2002; 91:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/27\">",
"      Soffer O, Nassar VH, Campbell WG Jr, Bourke E. Light chain cast nephropathy and acute renal failure associated with rifampin therapy. Renal disease akin to myeloma kidney. Am J Med 1987; 82:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/28\">",
"      Barill&eacute; S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995; 86:3151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/29\">",
"      Fattori E, Della Rocca C, Costa P, et al. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 1994; 83:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/30\">",
"      Sengul S, Zwizinski C, Simon EE, et al. Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int 2002; 62:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/31\">",
"      Sengul S, Zwizinski C, Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol 2003; 284:F1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/32\">",
"      Arimura A, Li M, Batuman V. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 2006; 107:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/33\">",
"      Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/34\">",
"      Leung N, Gertz M, Kyle RA, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol 2012; 7:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/35\">",
"      Buxbaum JN, Chuba JV, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 1990; 112:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/36\">",
"      Hill GS, Morel-Maroger L, M&eacute;ry JP, et al. Renal lesions in multiple myeloma: their relationship to associated protein abnormalities. Am J Kidney Dis 1983; 2:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22551/abstract/37\">",
"      Nowrousian MR, Brandhorst D, Sammet C, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11:8706.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7201 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22551=[""].join("\n");
var outline_f22_1_22551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role of tubular injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Light chain characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cast nephropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Amyloid deposits and LCDD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Renal tubular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other associated diagnoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Interleukin-6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NF-kappaB and MAPKs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7201\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7201|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/31/30206\" title=\"figure 1\">",
"      Differences in urinary albumin multiple myeloma and amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7201|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/40/41603\" title=\"picture 1A\">",
"      Myeloma cast I-light microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/30/33253\" title=\"picture 1B\">",
"      Myeloma cast II- light microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/60/13248\" title=\"picture 1C\">",
"      Myeloma kidney-immunofluorescence microscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9378?source=related_link\">",
"      Chapter 4D: Tamm-Horsfall mucoprotein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=related_link\">",
"      Treatment of kidney disease in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_1_22552="Gastric MALToma Low";
var content_f22_1_22552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extranodal marginal zone lymphoma (MALT) of the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a gastric MALToma (mucosa-associated lymphoid tissue tumor) shows dense, monotonous, lymphoid infiltrate in the lamina propria, and pale- staining cells consistent with marginal zone B-cells surrounding and infiltrating the epithelium (lymphoepithelial lesion).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nancy Lee Harris, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22552=[""].join("\n");
var outline_f22_1_22552=null;
var title_f22_1_22553="Chronic mucocutaneous candidiasis";
var content_f22_1_22553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic mucocutaneous candidiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/1/22553/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22553/contributors\">",
"     Chaim M Roifman, MD, FRCPC, FCACB",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/1/22553/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22553/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/1/22553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22553/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/1/22553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H571977\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic mucocutaneous candidiasis (CMCC) is a heterogeneous group of syndromes with common features including chronic noninvasive Candida infections of the skin, nails, and mucous membranes and associated autoimmune manifestations (most commonly endocrinopathies). It is caused by genetic faults in the immune system.",
"   </p>",
"   <p>",
"    An overview of CMCC is given and the pathogenesis and clinical manifestations of identified genetic defects leading to CMCC are reviewed here. The differential diagnosis and treatment of CMCC are also discussed. A general discussion of Candida infections and their clinical manifestations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31481?source=see_link\">",
"     \"Overview of Candida infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10714495\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMCC was first described in 1929 by Thorpe and Handley [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] followed by a more extensive description in the fifties and sixties [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. CMCC traditionally referred to a heterogeneous group of patients who suffered persistent noninvasive Candida infections of the skin, mucous membranes, and nails as well as autoimmune manifestations, most commonly involving the endocrine system.",
"   </p>",
"   <p>",
"    Mutations in the autoimmune regulator (AIRE) gene lead to CMCC in distinct populations, such as the Finns and Sardinians [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, the majority of patients with CMCC outside of these ethnic groups do not carry mutations in this gene. Most papers related to CMCC were published prior to the discovery of AIRE, making it impossible to correlate phenotypes with the AIRE genotype in most publications.",
"   </p>",
"   <p>",
"    Progress in techniques that will allow for whole genome sequencing as well as development of novel bioinformatic models should improve our understanding of the genetic causes of CMCC. These methodologies should also unravel phenotype diversity in classical Mendelian inherited disorders, such as AIRE deficiency. Fundamental questions, such as why these patients are susceptible to infections with Candida, are just beginning to be answered.",
"   </p>",
"   <p>",
"    CMCC is associated with a variety of clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune manifestations other than endocrinopathy, including autoimmune hemolytic anemia, immune thrombocytopenia purpura, autoimmune neutropenia, and rheumatoid arthritis have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Various degrees of bone marrow failure with aplastic anemia have been observed [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neoplastic diseases have occurred in several patients, mostly involving the mouth and esophagus. Benign and malignant thymomas are also reported [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple abnormalities in the immune system are reported in patients with CMCC:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most common is in vitro anergy of T cells to stimulation with Candida antigen [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/13\">",
"       13",
"      </a>",
"      ]. Lymphopenia and abnormal in vitro responses to mitogens have also been reported. However, these cohorts included patients with secondary immunodeficiency due to HIV infection, making it difficult to attribute such abnormalities to CMCC. In the cohort of patients followed by the author&rsquo;s group, 20 percent with non-AIRE deficiency-CMCC had reduced number",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      function of circulating T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Susceptibility to bacterial and viral infections was identified in 50 percent of patients in one cohort [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/15\">",
"       15",
"      </a>",
"      ]. Severe lung infections and sepsis were the cause of death in some of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/16\">",
"       16",
"      </a>",
"      ]. Patients with AIRE deficiency do not display a predisposition to bacterial and viral infections.",
"     </li>",
"     <li>",
"      Humoral deficiencies were also reported in patients with CMCC. In one series, four patients with recurrent pulmonary infections causing chronic lung disease and bronchiectasis all had normal serum immunoglobulin levels, but reduced antibody responses to immunization with polysaccharide antigens and decreased IgG2 and IgG4 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/16\">",
"       16",
"      </a>",
"      ]. In another series, nine patients with CMCC and recurrent infections were unable to respond adequately to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/17\">",
"       17",
"      </a>",
"      ]. All cases reported by the author&rsquo;s group had no mutations in the AIRE gene. Two of these patients as well as three other patients with antibody deficiency had a Lyp mutation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before effective oral antifungal drugs became available, there were attempts to treat CMCC with transplantation of thymus tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/18-20\">",
"     18-20",
"    </a>",
"    ] or HLA matched peripheral blood leukocyte infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. All showed limited and short-lived clinical improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H571991\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE REGULATOR (AIRE) DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune regulator (AIRE) deficiency accounts for the majority of CMCC cases in distinct populations, such as the Finns and Sardinians, but only 20 to 40 percent of cases in other populations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/6\">",
"     6",
"    </a>",
"    ]. The AIRE gene is localized to chromosome 21q 22.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients suffer chronic candidiasis as well as autoimmune polyendocrinopathy, most commonly hypoparathyroidism and adrenal insufficiency, and skin dystrophy, hence the name given to this disorder:",
"    <strong>",
"     autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)",
"    </strong>",
"    (MIM 240300). The disorder is also referred to as autoimmune polyendocrine syndrome type I (APS-I or APS1). The condition is transmitted in an autosomal recessive manner and is detected at a frequency of 1:9000 in Iranian Jews, 1:14,500 in Sardinians, and 1:25,000 in Finns. More than fifty mutations have been described so far, with the most common mutation being R257X in the Finnish population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10714680\">",
"    <span class=\"h2\">",
"     Pathogenesis of AIRE deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Random rearrangement of antigen-specific receptor genes during lymphocyte maturation produces a diverse repertoire of receptors including some able to recognize the body&rsquo;s own antigens. To prevent autoimmunity, thymocytes expressing self-reactive T cell receptors are eliminated. This selection process is primarily mediated by stromal cells (macrophages, dendritic cells) in the thymus that purge the repertoire of self-reactive T cell receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/23\">",
"     23",
"    </a>",
"    ]. A subpopulation of stromal cells, called medullary epithelial cells (MECs), express a vast spectrum of peripheral tissue autoantigens. MECs present these antigens to differentiating T cells and only the cells that recognize the autoantigens with high affinity are clonally deleted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/24\">",
"     24",
"    </a>",
"    ]. Expression of many of these autoantigens is regulated by the transcription factor, autoimmune regulator (AIRE) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Abnormal AIRE allows for forbidden T cells expressing autoreactive T cell receptors to expand to the periphery and induce autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Humans and mice with a mutated AIRE gene suffer multiorgan autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The endocrine system is most commonly involved. The severity of the inflammation and the",
"    <span class=\"nowrap\">",
"     organs/systems",
"    </span>",
"    targeted vary with genetic background (HLA-DR) in both species. As examples, HLA-DRB1*15-DQB1*0602 appears protective against type 1 diabetes mellitus, [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] while HLA-DRB1*04-DQB1*0302 is associated with alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/31\">",
"     31",
"    </a>",
"    ] and HLA-DRB1*DQ1*0602 is associated with adrenal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmunity in both humans and mice is associated with increased levels of autoantibodies against proteins made specifically by the affected organs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. These autoantibodies may have some predictive value. However, serum from AIRE knockout mice loaded with autoantibodies was incapable of inducing autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/34\">",
"     34",
"    </a>",
"    ]. In contrast, deletion of B cells with anti-CD20 antibody resulted in improvement of autoimmunity, suggesting that antigen presentation by B cells to T cells is critical in the pathogenesis of CMCC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/34\">",
"     34",
"    </a>",
"    ]. Autoantibodies against IL-17 and IL-22 were identified in the serum of patients with AIRE deficiency, suggesting that susceptibility to Candida infections has an autoimmune basis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Another study found impaired Th17 responses to Candida in patients with AIRE deficiency and other types of CMCC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/38\">",
"     38",
"    </a>",
"    ]. Further investigation is needed.",
"   </p>",
"   <p>",
"    Susceptibility to candidal infection in patients with AIRE deficiency may result from both abnormal adaptive and innate immunity. Dectin-1 is a beta-glucan receptor involved in the innate immune response to candidal infection. AIRE associates with components of the Dectin-1 signaling pathway, including Dectin-1, Syk, and caspase recruitment domain-containing protein 9 (CARD9) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/39\">",
"     39",
"    </a>",
"    ]. The trace constitutive association increases with stimulation of the Dectin-1 pathway, resulting in production of tumor necrosis factor-alpha (TNF-&alpha;). TNF-&alpha; production after stimulation of the Dectin-1 pathway is reduced in patients with AIRE deficiency. (See",
"    <a class=\"local\" href=\"#H572040\">",
"     'Dectin-1 deficiency'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H572069\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H571998\">",
"    <span class=\"h2\">",
"     Clinical features of AIRE deficiency/APECED",
"    </span>",
"    &nbsp;&mdash;&nbsp;APECED is known for its wide variation in clinical presentation and course of disease, even among affected family members carrying an identical genetic aberration. In addition, the disease may present with rare manifestations that persist for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/6,40\">",
"     6,40",
"    </a>",
"    ]. This clinical heterogeneity can lead to a significant delay in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/41\">",
"     41",
"    </a>",
"    ]. The first manifestation of the disease can start between the ages of 2 months to 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic triad is mucocutaneous candidiasis, hypoparathyroidism, and adrenal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic, or sometimes recurrent, candidal infection of the oral cavity, nails, and skin, and less frequently the esophagus, vagina, and gastrointestinal tract, is the presenting feature in 60 percent of patients and affects all patients by the time they are 40 years old. Skin lesions are frequently raised and sometimes disfiguring. Similarly, affected nail beds result in structurally malformed nails. These changes are probably due to a combination of infection and an exaggerated inflammatory (autoimmune) response (",
"      <a class=\"graphic graphic_picture graphicRef59947 \" href=\"UTD.htm?2/53/2911\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef71698 \" href=\"UTD.htm?28/24/29070\">",
"       picture 2",
"      </a>",
"      ). Candida albicans is the most common species to cause infection.",
"     </li>",
"     <li>",
"      Hypoparathyroidism is the most common endocrine abnormality in this disease and the second most common feature in AIRE deficiency, occurring at presentation in about 30 percent of patients. More than 80 percent of patients are eventually afflicted. Hypoparathyroidism appears earlier and is more common in females than males. The resultant hypocalcemia and hypomagnesemia is sometimes hard to control and may lead to seizures.",
"     </li>",
"     <li>",
"      Adrenal failure is the third most common feature in the disease. It occurs in only about 5 percent at presentation, but occurs in more than 60 percent of cases by the age of 15 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other manifestations are less common [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other endocrinopathies include type 1 diabetes mellitus, hypothyroidism, growth hormone deficiency, ovarian failure (appears to coexist with adrenal failure), and male hypogonadism.",
"     </li>",
"     <li>",
"      Other autoimmune manifestations include vitiligo and alopecia areata, which affects more than 30 percent of patients after the age of 20 years and can progress to universal baldness. Pernicious anemia affects more than 20 percent of patients after the age of 30 years. Hepatitis is rare.",
"     </li>",
"     <li>",
"      Complications presumed due to chronic Candida infection include keratoconjunctivitis, which may lead to blindness, esophageal stricture, and squamous cell carcinoma of the mouth and esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibody deficiency to polysaccharide antigens may occur.",
"     </li>",
"     <li>",
"      Other oral and gastrointestinal manifestations include enamel abnormalities, chronic diarrhea, and constipation.",
"     </li>",
"     <li>",
"      Other ocular features reported include cortical lenticular opacities and chronic iridocyclitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AIRE deficiency may also present with unusual features. Young children, even in their first year of life, may present with fever and periodic rash, dry eyes, exocrine pancreatic insufficiency, or renal involvement, including hypokalemia, hypertension, or tubular interstitial nephritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8501601\">",
"    <span class=\"h1\">",
"     AUTOSOMAL DOMINANT CMCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;A monoallelic mutation in the coiled&ndash;coil (cc) domain of signal transducer and activator of transcription 1 (STAT1) was identified in a cohort of families with a presumed autosomal dominant inheritance of CMCC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/43\">",
"     43",
"    </a>",
"    ]. The clinical manifestations in these patients are predominantly limited to the skin, nails, and mucous membranes, similar to patients with AIRE deficiency. Unlike cases with AIRE mutations, patients with mutation in the coiled-coil domain of STAT1 have no endocrine abnormalities except for hypothyroidism. The decreased production of interferon-&gamma;, interleukin-17, and interleukin-22 seen in the mononuclear cells of these patients suggests a defect in Th1 and Th17 responses. A gain-of-function causing impaired nuclear dephosphorylation of activated STAT1 was proposed as a mechanism for these mutations, possibly explaining the dominance of the mutant allele [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A heterozygous mutation in the DNA-binding domain of STAT1 that also causes autosomal dominant CMCC was identified in two unrelated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/45\">",
"     45",
"    </a>",
"    ]. Both patients had severe, recurrent oral thrush and sinopulmonary infections with Streptococcus pneumoniae. One patient had hypothyroidism and another developed hemophagocytic lymphohistiocytosis and Evans syndrome. This mutation has a similar mechanism of action to the cc domain mutations, with a gain-of-function in STAT1 due to impaired dephosphorylation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in other domains of STAT1 may produce different phenotypes, such as susceptibility to mycobacterial and viral infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4297?source=see_link&amp;anchor=H9#H9\">",
"     \"Mendelian susceptibility to mycobacterial diseases (MSMD)\", section on 'STAT1 deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10715373\">",
"    <span class=\"h1\">",
"     OTHER GENETIC ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other genetic aberrations are associated with far smaller numbers of cases and are frequently found in a single family. In some cases, inheritance may involve multiple genes, as is seen in some patients with Lyp [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/47\">",
"     47",
"    </a>",
"    ] and dectin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/48\">",
"     48",
"    </a>",
"    ] mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572091\">",
"    <span class=\"h2\">",
"     Lyp mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protein tyrosine phosphatase nonreceptor-type 22 (PTPN22) gene localized to 1p13 encodes lymphoid phosphatase, Lyp [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/49\">",
"     49",
"    </a>",
"    ]. The substrates of Lyp include the kinases Lck, Fyn, Zap-70, and the CD3-zeta chain of the T cell receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/50\">",
"     50",
"    </a>",
"    ]. In accordance with this observation, Lyp overexpression downregulates TCR signaling while Lyp deficiency enhances T cell activation. Lyp also interacts with the Src family negative regulatory kinase, Csk. Lyp and Csk act in tandem to negatively regulate activation of Src kinases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/51\">",
"     51",
"    </a>",
"    ]. The interaction between Lyp and Csk is lost in the R620W mutation of Lyp, since the arginine at this position is necessary for Csk-SH3 domain recognition of protein rich areas of Lyp. This mutation is also believed to result in gain of function that alters TCR signaling, resulting in possible compromised central as well as peripheral tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Six patients with CMCC who carried a R620W mutation of PTPN22 all had oral or skin candidiasis, similar to patients with AIRE mutations, but none had enamel defects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/47\">",
"     47",
"    </a>",
"    ]. The most common endocrine abnormalities were hypothyroidism and gonadal failure. None had hypoparathyroidism, the most common endocrine abnormality in AIRE deficiency. A unique finding seen in five of the patients with the R620W Lyp mutant was chronic lung disease including bronchiectasis. This is probably due to antibody deficiency in four of the six patients, another manifestation almost nonexistent in AIRE deficiency.",
"   </p>",
"   <p>",
"    The R620W mutant was previously found to be associated with a variety of autoimmune disorders including rheumatoid arthritis, Type 1 diabetes, SLE, and Addison disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/54-61\">",
"     54-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572040\">",
"    <span class=\"h2\">",
"     Dectin-1 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida albicans is recognized by the innate immune system through pattern-recognition receptors, such as the toll-like-receptors (TLRs) and lectin like-receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/62\">",
"     62",
"    </a>",
"    ]. TLR2, TLR4, and mannose receptors recognize mannans, Candida cell wall components [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. These receptors collaborate with the beta-glucan receptor Dectin-1 (MIM *606264) in stimulation of cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/65\">",
"     65",
"    </a>",
"    ]. Dectin-1 enhances TLR2 and TLR4 induced cytokine production, such as tumor necrosis factor. In its absence, mice have increased susceptibility to Candida albicans and Pneumocystis jirovecii (carinii) infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A family with Dectin-1 deficiency was identified in which affected members had a homozygous SNP in exon 6 that caused a change of amino acid 238 from tyrosine to a stop codon [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/48\">",
"     48",
"    </a>",
"    ]. These patients suffered vulvovaginitis and onychomycosis, but did not have invasive candidiasis, other major infections, or autoimmune manifestations. It therefore appears that Dectin-1 deficiency leads to a pure susceptibility to mucosal and skin, but not invasive, fungal infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10677880\">",
"    <span class=\"h2\">",
"     Toll-like receptor 3 defect (L412F mutant)",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLR3 plays a role in initiating adaptive immune responses, suppressing autoimmune disorders, and protecting against viral infection. Fourteen patients with no identified mutations in the other genes known to cause CMCC were found to carry the TLR3 L412F mutant that renders TLR3 dysfunctional [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/68\">",
"     68",
"    </a>",
"    ]. These patients were previously classified as a distinct clinical subgroup, CMCC with autoimmunity and combined immunodeficiency.",
"   </p>",
"   <p>",
"    The one patient who was homozygous for this variant had more severe disease with treatment-resistant oral and esophageal candidiasis; cytomegalovirus (CMV)-induced hepatitis, viremia, and pneumonitis; recurrent sinopulmonary infections; chronic lung disease with bronchiectasis; and thrombocytopenia, hemolytic anemia, and neutropenia.",
"   </p>",
"   <p>",
"    Patients heterozygous for the TLR3 variant all had chronic candidiasis and most had nail dystrophy, similar to other forms of CMCC. However, these patients also had severe chronic infections (mainly sinopulmonary), often leading to chronic lung disease and bronchiectasis. In addition, they had a high frequency of severe viral infections, particularly CMV, autoimmune disorders (eg, cytopenias), and endocrine abnormalities (eg, hypothyroidism). Rarely, these patients develop bone marrow failure, possibly due to CMV infections.",
"   </p>",
"   <p>",
"    Immune evaluation reveals antibody deficiency as well as abnormal in vitro proliferative responses to mitogens. Interferon gamma production was decreased in response to stimulation with a TLR3 ligand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10715462\">",
"    <span class=\"h1\">",
"     OTHER FORMS OF CMCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are other distinct forms of CMCC for which the genetic defects have not yet been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572055\">",
"    <span class=\"h2\">",
"     CMCC with cerebral vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients with skin and mucosal candidiasis suffer severe events of cerebral vasculitis indistinguishable from Moyamoya disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/69\">",
"     69",
"    </a>",
"    ]. The mode of inheritance appears to be autosomal dominant, but the genetic defect in this group of patients remains largely unknown. Sequence analysis of the coding region of the AIRE, CD25, dectin-1 and CARD9 genes were normal in these patients, although some of these patients were found to have monoallelic mutations in",
"    <em>",
"     STAT1",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=see_link\">",
"     \"Moyamoya disease: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients have mucosal candidiasis and most have nail dystrophy, similar to patients with AIRE deficiency. Most do not display endocrine abnormalities, except for hypothyroidism. Recurrent infections, especially pneumonia and sinusitis, are common in this group of patients and some develop bronchiectasis over time. Squamous cell carcinoma of the skin may develop, similar to patients with AIRE deficiency. (See",
"    <a class=\"local\" href=\"#H571998\">",
"     'Clinical features of AIRE deficiency/APECED'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29999189\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CMCC is primarily based upon clinical features including chronic, noninvasive candidiasis of the skin and mucous membranes associated with autoimmune manifestations, most commonly endocrinopathies. The diagnosis can be confirmed in some cases by identifying a disease-causing mutation in the AIRE gene. Other patients have genetic alterations in Lyp or Dectin-1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29999197\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with chronic candidiasis should be evaluated for primary and secondary immunodeficiencies. This should include a complete blood count with differential, immunoglobulin levels including IgE level, and B and T cell subsets at a minimum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=see_link\">",
"     \"Approach to the adult with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only definitive laboratory test for the diagnosis of CMCC is the genetic analysis of the AIRE gene for disease-causing mutations. Other laboratory findings are less definitive, but can aid in the diagnosis. These include standard laboratory tests to evaluate for endocrine disorders, such as hypoparathyroidism and adrenal insufficiency that are associated with CMCC. A blood count can reveal anemia, either due to iron deficiency (hypochronic, microcytic) or due to vitamin B12 deficiency (megaloblastic). Both may be caused by malabsorption and parietal cell atrophy. Liver function should also be screened, because hepatitis is rarely associated with CMCC.",
"   </p>",
"   <p>",
"    Evaluation of the immune system may identify a selective inability to respond in vitro (T cell proliferation) or in vivo (cutaneous delayed-type hypersensitivity) to Candida, especially in patients with AIRE deficiency. In others, more extensive abnormalities in in vitro antigenic and mitogenic responses are identified. Humoral immunity may also be affected, including low IgG2 and IgG4, hypogammaglobulinemia, and an inadequate response to vaccination with polysaccharide antigens (eg, unconjugated pneumococcal vaccine) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum Candida antibodies are not of value in the diagnosis of CMCC, nor are skin or serum IgE tests for Candida.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572069\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic candidiasis can be encountered in many types of primary immunodeficiencies. Most commonly profound primary or secondary T cell deficiencies predispose to susceptibility to Candida. Patients with severe combined immunodeficiency and acquired immunodeficiency almost invariably present with oral thrush",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with other cutaneous candida infections. However, unlike patients with CMCC, Candida infections in these disorders can become invasive with systemic spread. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): Specific defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"     \"Secondary immune deficiency due to miscellaneous causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, patients with caspase recruitment domain-containing protein 9 (CARD9) deficiency appear to have selective susceptibility to invasive candida infection in mice and humans, but do not have other features typically associated with CMCC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/71\">",
"     71",
"    </a>",
"    ]. CD25 deficiency, a combined immunodeficiency, can cause persistent oral and esophageal candidiasis. Other conditions, such as hyper IgE syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/72\">",
"     72",
"    </a>",
"    ] and ataxia telangiectasia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/72\">",
"     72",
"    </a>",
"    ] can also present with oral thrush, but common to all these conditions is the presence of other major clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H7#H7\">",
"     \"Combined immunodeficiencies\", section on 'Interleukin-2 receptor alpha chain (CD25) deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=see_link\">",
"     \"Hyperimmunoglobulin E syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic candidiasis is also seen in patients with diabetes mellitus, HIV infection, or in patients treated with systemic or inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/74\">",
"     74",
"    </a>",
"    ] or prolonged courses of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572076\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management includes antifungal therapy and treatment of associated endocrine and autoimmune abnormalities.",
"   </p>",
"   <p>",
"    Candidiasis usually clears with treatment with a member of the azole family, although chronic suppressive therapy is often required to prevent recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is the preferred treatment. It has good activity against C. albicans, is easy to administer, has few side effects, and is relatively inexpensive. Drug resistance may occur with suppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/79\">",
"     79",
"    </a>",
"    ]. The dose can be escalated if increasing resistance is an issue, but ultimately another azole agent will need to be used.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    can be tried, in that order. Liver function should be carefully monitored while patients are on systemic therapy with these drugs. Amphotericin has been successfully used in severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=see_link\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Azoles'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. albicans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endocrine abnormalities should be treated with replacement therapy when possible [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/40,75\">",
"     40,75",
"    </a>",
"    ]. In cases of hypoparathyroidism, calcium levels should be carefully monitored and calcium supplementation should be given. Frequently, magnesium must be given to avoid seizures that can be caused by hypomagnesemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=see_link\">",
"     \"Evaluation and treatment of hypomagnesemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31078?source=see_link\">",
"     \"Treatment of adrenal insufficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibody deficiency, if severe, should be treated with immune globulin replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is little experience in controlling severe autoimmune manifestations in CMCC.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two weeks was effective in resolving autoimmune panniculitis in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/81\">",
"     81",
"    </a>",
"    ]. In another case, prednisone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, which were given to prevent renal transplant rejection, reversed multiple autoimmune manifestations and reduced levels of autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/82\">",
"     82",
"    </a>",
"    ]. Prednisone in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    was effective in improving autoimmune hepatitis in another patient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/6,29\">",
"     6,29",
"    </a>",
"    ]. Severe malabsorption was reversed in one patient with a pulse of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/83\">",
"     83",
"    </a>",
"    ]. Deletion of B cells with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    improved autoimmune manifestations in mice and could potentially be effective in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two reports of successful hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22553/abstract/11,84\">",
"     11,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Future studies should determine the most effective and least toxic treatment for each of the manifestations experienced by these patients. Until such information is available, each option should be carefully considered, with benefits outweighing risks of treatment. One way of approaching this issue is to start with the least toxic medications and escalate treatment as needed. A combination of immunosuppressive drugs may also allow for reduced doses of each agent and thus reduced toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10714482\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic mucocutaneous candidiasis (CMCC) is a heterogeneous group of syndromes with common features including chronic noninvasive Candida infections of the skin, nails, and mucous membranes and associated autoimmune manifestations (most commonly endocrinopathies). (See",
"      <a class=\"local\" href=\"#H571977\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10714495\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMCC is caused by genetic faults in the immune system. Genetic defects affecting autoimmune regulator (AIRE), lymphoid phosphatase (Lyp), and the beta-glucan receptor dectin-1 have been identified in some patients. However, the genetic defect has not been identified in all patients and inheritance may involve multiple genes in some cases. (See",
"      <a class=\"local\" href=\"#H571991\">",
"       'Autoimmune regulator (AIRE) deficiency'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10715373\">",
"       'Other genetic associations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10715462\">",
"       'Other forms of CMCC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of CMCC includes primary and secondary immunodeficiencies that affect T cell function, including combined immunodeficiencies, such as CD25 deficiency, and severe combined immunodeficiency (SCID). Chronic candidiasis is also seen in patients treated with systemic or inhaled glucocorticoids or prolonged courses of antibiotics. (See",
"      <a class=\"local\" href=\"#H572069\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management includes antifungal therapy and treatment of associated endocrine and autoimmune abnormalities. (See",
"      <a class=\"local\" href=\"#H572076\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/1\">",
"      Thorpe ES, Handley HE. Chronic tetany and chronic mycelia stomatitis in a child aged four and one half years. Am J Dis Child 1929; 38:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/2\">",
"      CRAIG JM, SCHIFF LH, BOONE JE. Chronic moniliasis associated with Addison's disease. AMA Am J Dis Child 1955; 89:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/3\">",
"      ESSELBORN VM, LANDING BH, WHITAKER J, WILLIAMS RR. The syndrome of familial juvenile hypoadrenocorticism, hypoparathyroidism and superficial moniliasis. J Clin Endocrinol Metab 1956; 16:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/4\">",
"      HUNG W, MIGEON CJ, PARROTT RH. A POSSIBLE AUTOIMMUNE BASIS FOR ADDISON'S DISEASE IN THREE SIBLINGS, ONE WITH IDIOPATHIC HYPOPARATHYROIDISM, PERNICIOUS ANEMIA AND SUPERFICIAL MONILIASIS. N Engl J Med 1963; 269:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/5\">",
"      Blizzard RM, Gibbs JH. Candidiasis: studies pertaining to its association with endocrinopathies and pernicious anemia. Pediatrics 1968; 42:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/6\">",
"      Ahonen P, Myll&auml;rniemi S, Sipil&auml; I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/7\">",
"      Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/8\">",
"      Herrod HG. Chronic mucocutaneous candidiasis in childhood and complications of non-Candida infection: a report of the Pediatric Immunodeficiency Collaborative Study Group. J Pediatr 1990; 116:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/9\">",
"      Oyefara BI, Kim HC, Danziger RN, et al. Autoimmune hemolytic anemia in chronic mucocutaneous candidiasis. Clin Diagn Lab Immunol 1994; 1:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/10\">",
"      Twomey JJ, Waddell CC, Krantz S, et al. Chronic mucocutaneous candidiasis with macrophage dysfunction, a plasma inhibitor, and co-existent aplastic anemia. J Lab Clin Med 1975; 85:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/11\">",
"      Deeg HJ, Lum LG, Sanders J, et al. Severe aplastic anemia associated with chronic mucocutaneous candidiasis. Immunologic and hematologic reconstitution after allogeneic bone marrow transplantation. Transplantation 1986; 41:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/12\">",
"      Kirkpatrick CH, Windhorst DB. Mucocutaneous candidiasis and thymoma. Am J Med 1979; 66:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/13\">",
"      Kirkpatrick CH, Chandler JW, Schimke RN. Chronic mucocutaneous moniliasis with impaired delayed hypersensitivity. Clin Exp Immunol 1970; 6:375.",
"     </a>",
"    </li>",
"    <li>",
"     Nahum A, Roifman CM, et al, 2010, personal communication.",
"    </li>",
"    <li>",
"     Kirkpatrick CH, Sohnle PG. Chronic mucocutaneous candidiasis. In: Immunodermatology, Safai B, Good RA (Eds), Plenum Press, New York 1981. p.495.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/16\">",
"      Bentur L, Nisbet-Brown E, Levison H, Roifman CM. Lung disease associated with IgG subclass deficiency in chronic mucocutaneous candidiasis. J Pediatr 1991; 118:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/17\">",
"      Kalfa VC, Roberts RL, Stiehm ER. The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency. Ann Allergy Asthma Immunol 2003; 90:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/18\">",
"      Levy RL, Bach ML, Huang S, et al. Thymic transplantation in a case of chronic mucocutaneous candidiasis. Lancet 1971; 2:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/19\">",
"      Kirkpatrick CH, Ottenson EA, Smith TK, et al. Reconstitution of defective cellular immunity with foetal thymus and dialysable transfer factor. Long-term studies in a patient with chronic mucocutaneous candidiasis. Clin Exp Immunol 1976; 23:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/20\">",
"      Ballow M, Hyman LR. Combination immunotherapy in chronic mucocutaneous candidiasis. Synergism between transfer factor and fetal thymus tissue. Clin Immunol Immunopathol 1977; 8:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/21\">",
"      Valdimarsson H, Moss PD, Holt PJ, H OBBS JR. Treatment of chronic mucocutaneous candidiasis with leucocytes from HL-A compatible sibling. Lancet 1972; 1:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/22\">",
"      Kirkpatrick CH, Rich RR, Graw RG Jr, et al. Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution. Clin Exp Immunol 1971; 9:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/23\">",
"      Siggs OM, Makaroff LE, Liston A. The why and how of thymocyte negative selection. Curr Opin Immunol 2006; 18:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/24\">",
"      Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol 2006; 24:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/25\">",
"      Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002; 298:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/26\">",
"      Anderson MS, Venanzi ES, Chen Z, et al. The cellular mechanism of Aire control of T cell tolerance. Immunity 2005; 23:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/27\">",
"      Liston A, Lesage S, Wilson J, et al. Aire regulates negative selection of organ-specific T cells. Nat Immunol 2003; 4:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/28\">",
"      Ramsey C, Winqvist O, Puhakka L, et al. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum Mol Genet 2002; 11:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/29\">",
"      Betterle C, Greggio NA, Volpato M. Clinical review 93: Autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1998; 83:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/30\">",
"      Karvonen M, Viik-Kajander M, Moltchanova E, et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/31\">",
"      Halonen M, Eskelin P, Myhre AG, et al. AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol Metab 2002; 87:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/32\">",
"      Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002; 23:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/33\">",
"      Yu L, Brewer KW, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 1999; 84:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/34\">",
"      Gavanescu I, Benoist C, Mathis D. B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: A therapeutic approach for APECED patients. Proc Natl Acad Sci U S A 2008; 105:13009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/35\">",
"      Puel A, D&ouml;ffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010; 207:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/36\">",
"      Kisand K, B&oslash;e Wolff AS, Podkrajsek KT, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010; 207:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/37\">",
"      Browne SK, Holland SM. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect Dis 2010; 10:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/38\">",
"      Ng WF, von Delwig A, Carmichael AJ, et al. Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Allergy Clin Immunol 2010; 126:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/39\">",
"      Pedroza LA, Kumar V, Sanborn KB, et al. Autoimmune regulator (AIRE) contributes to Dectin-1-induced TNF-&alpha; production and complexes with caspase recruitment domain-containing protein 9 (CARD9), spleen tyrosine kinase (Syk), and Dectin-1. J Allergy Clin Immunol 2012; 129:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/40\">",
"      Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006; 91:2843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/41\">",
"      Mazza C, Buzi F, Ortolani F, et al. Clinical heterogeneity and diagnostic delay of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Clin Immunol 2011; 139:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/42\">",
"      Richman RA, Rosenthal IM, Solomon LM, Karachorlu KV. Candidiasis and multiple endocrinopathy. With oral squamous cell carcinoma complications. Arch Dermatol 1975; 111:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/43\">",
"      van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/44\">",
"      Liu L, Okada S, Kong XF, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/45\">",
"      Takezaki S, Yamada M, Kato M, et al. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol 2012; 189:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/46\">",
"      Mar&oacute;di L, Cypowyj S, T&oacute;th B, et al. Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol 2012; 130:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/47\">",
"      Nahum A, Bates A, Sharfe N, Roifman CM. Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008; 122:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/48\">",
"      Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/49\">",
"      Cohen S, Dadi H, Shaoul E, et al. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 1999; 93:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/50\">",
"      Wu J, Katrekar A, Honigberg LA, et al. Identification of substrates of human protein-tyrosine phosphatase PTPN22. J Biol Chem 2006; 281:11002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/51\">",
"      Gj&ouml;rloff-Wingren A, Saxena M, Williams S, et al. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol 1999; 29:3845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/52\">",
"      Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/53\">",
"      Gregorieff A, Cloutier JF, Veillette A. Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). J Biol Chem 1998; 273:13217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/54\">",
"      Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/55\">",
"      Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 2006; 18:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/56\">",
"      Criswell LA, Pfeiffer KA, Lum RF, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005; 76:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/57\">",
"      Hinks A, Eyre S, Barton A, et al. Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. Ann Rheum Dis 2007; 66:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/58\">",
"      Kaufman KM, Kelly JA, Herring BJ, et al. Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus. Arthritis Rheum 2006; 54:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/59\">",
"      Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/60\">",
"      Lee AT, Li W, Liew A, et al. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun 2005; 6:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/61\">",
"      Qu H, Tessier MC, Hudson TJ, Polychronakos C. Confirmation of the association of the R620W polymorphism in the protein tyrosine phosphatase PTPN22 with type 1 diabetes in a family based study. J Med Genet 2005; 42:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/62\">",
"      Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008; 6:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/63\">",
"      Netea MG, Gow NA, Munro CA, et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 2006; 116:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/64\">",
"      Jouault T, Ibata-Ombetta S, Takeuchi O, et al. Candida albicans phospholipomannan is sensed through toll-like receptors. J Infect Dis 2003; 188:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/65\">",
"      Brown GD, Herre J, Williams DL, et al. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 2003; 197:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/66\">",
"      Taylor PR, Tsoni SV, Willment JA, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 2007; 8:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/67\">",
"      Gantner BN, Simmons RM, Canavera SJ, et al. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003; 197:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/68\">",
"      Nahum A, Dadi H, Bates A, Roifman CM. The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. J Allergy Clin Immunol 2011; 127:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/69\">",
"      Grouhi M, Dalal I, Nisbet-Brown E, Roifman CM. Cerebral vasculitis associated with chronic mucocutaneous candidiasis. J Pediatr 1998; 133:571.",
"     </a>",
"    </li>",
"    <li>",
"     Roifman C, University of Toronto, 2012, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/71\">",
"      Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/72\">",
"      Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/73\">",
"      Ersoy F, Berkel AI, Sanal O, Oktay H. Twenty-year follow-up of 160 patients with ataxia-telangiectasia. Turk J Pediatr 1991; 33:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/74\">",
"      Fukushima C, Matsuse H, Tomari S, et al. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol 2003; 90:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/75\">",
"      Hachiya KA, Kobayashi RH, Antonson DL. Candida esophagitis following antibiotic usage. Pediatr Infect Dis 1982; 1:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/76\">",
"      Husebye ES, Perheentupa J, Rautemaa R, K&auml;mpe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 2009; 265:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/77\">",
"      Burke WA. Use of itraconazole in a patient with chronic mucocutaneous candidiasis. J Am Acad Dermatol 1989; 21:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/78\">",
"      Kirkpatrick CH. Chronic mucocutaneous candidiasis. Pediatr Infect Dis J 2001; 20:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/79\">",
"      Kamai Y, Maebashi K, Kudoh M, et al. Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis. Microbiol Immunol 2004; 48:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/80\">",
"      Rautemaa R, Richardson M, Pfaller MA, et al. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn Microbiol Infect Dis 2008; 62:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/81\">",
"      F&uuml;chtenbusch M, Vogel A, Achenbach P, et al. Lupus-like panniculitis in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Exp Clin Endocrinol Diabetes 2003; 111:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/82\">",
"      Ulinski T, Perrin L, Morris M, et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome with renal failure: impact of posttransplant immunosuppression on disease activity. J Clin Endocrinol Metab 2006; 91:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/83\">",
"      Padeh S, Theodor R, Jonas A, Passwell JH. Severe malabsorption in autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy syndrome successfully treated with immunosuppression. Arch Dis Child 1997; 76:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22553/abstract/84\">",
"      Hoh MC, Lin HP, Chan LL, Lam SK. Successful allogeneic bone marrow transplantation in severe chronic mucocutaneous candidiasis syndrome. Bone Marrow Transplant 1996; 18:797.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13569 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22553=[""].join("\n");
var outline_f22_1_22553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10714482\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H571977\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10714495\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H571991\">",
"      AUTOIMMUNE REGULATOR (AIRE) DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10714680\">",
"      Pathogenesis of AIRE deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H571998\">",
"      Clinical features of AIRE deficiency/APECED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8501601\">",
"      AUTOSOMAL DOMINANT CMCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10715373\">",
"      OTHER GENETIC ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H572091\">",
"      Lyp mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H572040\">",
"      Dectin-1 deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10677880\">",
"      Toll-like receptor 3 defect (L412F mutant)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10715462\">",
"      OTHER FORMS OF CMCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H572055\">",
"      CMCC with cerebral vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29999189\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29999197\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H572069\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H572076\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10714482\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/13569\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13569|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/53/2911\" title=\"picture 1\">",
"      Oral candidiasis in a patient with CMCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/24/29070\" title=\"picture 2\">",
"      Candidal onychomycosis in a patient with CMCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=related_link\">",
"      Approach to the adult with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=related_link\">",
"      Clinical manifestations of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4297?source=related_link\">",
"      Mendelian susceptibility to mycobacterial diseases (MSMD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31481?source=related_link\">",
"      Overview of Candida infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=related_link\">",
"      Severe combined immunodeficiency (SCID): Specific defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31078?source=related_link\">",
"      Treatment of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_1_22554="Management and prevention of complications of head and neck cancer during initial treatment";
var content_f22_1_22554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and prevention of complications of head and neck cancer during initial treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/1/22554/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22554/contributors\">",
"     Thomas Galloway, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22554/contributors\">",
"     Robert J Amdur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/1/22554/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22554/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22554/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22554/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22554/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/1/22554/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/1/22554/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/1/22554/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxicity from cancer therapy is classified as acute or late based upon its temporal relationship to treatment. Acute toxicity develops during or shortly after the completion of treatment and is usually temporary. Late toxicity presents months to years after the completion of treatment and is often permanent. The term complication is used for a treatment toxicity that causes an important medical problem.",
"   </p>",
"   <p>",
"    This topic will review the care of patients with head and neck cancer during their initial therapy, both to treat acute toxicity and to prevent late complications. The management of late complications is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1057183973\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Spectrum of issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers of the upper aerodigestive tract are in close proximity to organs vital to a patient&rsquo;s quality of life (eg, tongue, larynx, mandible), and they often emanate from such organs. The involvement of these structures with cancer and the steps needed to eradicate the malignancy can cause a wide spectrum of toxicities.",
"   </p>",
"   <p>",
"    The most basic toxicities are the impairment in the ability to breathe, communicate, and maintain an adequate oral intake. Oral intake is compromised by swallowing problems (dysphagia and odynophagia), poor taste (dysgeusia), trismus, xerostomia, and mucositis. Respiration and communication can be compromised by bulky tumors, neuromuscular impairment secondary to tumor growth, or an edematous pharynx",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    larynx. In addition to toxicity limiting the ability to speak, eat, and breathe, patients can experience cutaneous toxicity from both radiation and targeted therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ), neurotoxicity from both commonly used chemotherapy agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) and radiation, and dental complications from the effects of radiation dose to the",
"    <span class=\"nowrap\">",
"     mandible/maxilla",
"    </span>",
"    and salivary glands.",
"   </p>",
"   <p>",
"    The treatment of these tumors is complex and best handled by a coordinated team involving surgeons, radiation oncologists, medical oncologists, dentists, oral surgeons, speech pathologists,",
"    <span class=\"nowrap\">",
"     physical/occupational",
"    </span>",
"    therapists, nutritionists, and skilled nurses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most surgical complications are subsite specific. Common to any of the surgical procedures is the possibility of cosmetic deformities or functional impairment. With the development of soft tissue transfers, advances in surgical techniques, and organ preservation approaches, these are less common than they were in the past. Nonetheless, major or even minor surgical defects in these areas may be very evident because of their location on the face and neck, resulting in emotional and psychological distress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most radiation therapy (RT) toxicity can be divided into acute toxicity, which is largely unavoidable but transient, and late toxicity, which can be minimized but is generally long-lasting and in some instances permanent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute toxicity is defined as events that happen during radiation therapy or within 90 days after the commencement of treatment. While a sophisticated understanding of dose response relationships for normal tissues of interest (eg, parotid gland, larynx, pharyngeal constrictors) can reduce late toxicity, efforts to minimize acute toxicity have been less successful. The simplest and most important way to minimize acute toxicity is to avoid overtreatment (ie, not treat unnecessarily large target volumes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the complications of chemotherapy given for head and neck cancer are not unique to these patients. The most commonly used drugs include the platinum compounds (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ), 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    , and the taxanes (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ). Myelosuppression and nausea and vomiting are significant side effects with all of these agents.",
"   </p>",
"   <p>",
"    Toxicities of particular note in the context of head and neck cancer treatment include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       Fluorouracil",
"      </a>",
"      commonly causes mucositis even when given without radiation. Fluorouracil is often given by prolonged infusion in head and neck cancer protocols; this regimen increases the incidence of mucositis and diarrhea, as well as cardiotoxicity and acral erythema (also called hand-foot syndrome or palmar-plantar erythrodysesthesia), compared with daily intravenous bolus administration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link\">",
"       \"Oral toxicity associated with chemotherapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"       \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=see_link&amp;anchor=H23#H23\">",
"       \"Cutaneous complications of conventional chemotherapy agents\", section on 'Acral erythema (hand-foot skin reaction)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      is an important potential cause of nephrotoxicity, neurotoxicity, and ototoxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"       \"Cisplatin nephrotoxicity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link&amp;anchor=H2#H2\">",
"       \"Neurologic complications of platinum-based chemotherapy\", section on 'Cisplatin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The taxanes can cause an acute allergic reaction during or shortly after drug infusion, in addition to myelosuppression and neurotoxicity. Allergic reactions can usually be prevented by pretreatment with steroids. Fluid retention often occurs with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , and its onset can be delayed with concomitant treatment with corticosteroids [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H32#H32\">",
"       \"Infusion reactions to systemic chemotherapy\", section on 'Taxanes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       Fluorouracil",
"      </a>",
"      , taxanes, and platinum agents exacerbate the severity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      duration of radiation induced mucositis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       Cetuximab",
"      </a>",
"      can cause an acute hypersensitivity reaction, which can be minimized with antihistamines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H48#H48\">",
"       \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Cetuximab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       Cetuximab",
"      </a>",
"      exacerbates radiation-induced skin reactions within the treatment volume and can also cause significant cutaneous toxicity outside of the treatment fields [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H168427314#H168427314\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Cetuximab plus cisplatin plus RT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H707302341\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should receive counseling about the importance of smoking cessation. Besides being a major risk factor for head and neck cancer, smoking may influence the prognosis of the cancer. When smoking is continued during and after RT, it can increase the severity and duration of mucosal reactions, exacerbate xerostomia, and compromise oncologic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, one study evaluated 115 patients with head and neck cancer who were treated with RT with or without 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/5\">",
"     5",
"    </a>",
"    ]. The 53 patients who continued to smoke during RT had significantly lower rates of complete response and two-year survival compared with the 62 patients who did not smoke or who had quit prior to treatment (45 versus 74 percent and 39 versus 66 percent, respectively). Among nonsmoking patients, mortality rate was influenced by the duration since quitting smoking. Compared to patients who continued to smoke, the death rate was 40 percent lower in patients who had quit less than 12 weeks before and 70 percent lower in patients who had quit more than one year before diagnosis.",
"   </p>",
"   <p>",
"    Although the epidemiology of head and neck cancer is changing with the emergence of HPV associated oropharyngeal cancer, the importance of smoking cessation has not changed. In an unplanned analysis of RTOG 01-29, the mortality in the HPV positive group was higher for those patients who were smokers compared with nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SALIVARY GLAND DAMAGE AND XEROSTOMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454123\">",
"    <span class=\"h2\">",
"     Acute injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The salivary glands would be expected to be a late responding tissue with little acute effects because of their slow cellular turnover (60 to 120 days). However, changes in the quantity and composition of saliva that occur shortly after the initiation of RT indicate that these glands exhibit both an acute response and a late response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of the acute reaction of salivary gland cells is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. These effects are due to irradiation of both the major (parotid, submandibular, sublingual) salivary glands and the minor salivary glands that are scattered throughout the upper aerodigestive tract. Impaired oral intake due to mucositis or altered sensation of taste may also contribute to decreased saliva production. Comorbid conditions and the medications used to treat them may contribute significantly to the risk of both acute and long-term xerostomia. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Mucositis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H722455196\">",
"     'Dysgeusia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Temporary decreased saliva production becomes evident within one to two weeks after the initiation of RT, and permanent reduction can be noted with cumulative radiation doses as low as 10 to 15 Gy to the parotid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/11\">",
"     11",
"    </a>",
"    ]. During and immediately after treatment, patients should be instructed to drink adequate fluids and to rinse and gargle with either a dilute solution of 25 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    and 75 percent water or a weak solution of salt and baking soda several times daily (one-half teaspoon of salt and one teaspoon of baking soda added to one quart of water) during treatment. This regimen can refresh the mouth, loosen thick, tenacious oral secretions, and alleviate pain due to mild mucositis.",
"   </p>",
"   <p>",
"    Mean radiation doses to the parotid glands greater than 24 to 26 Gy cause permanent damage to the parotid glands, which typically results in more than a 75 percent reduction in salivary gland function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The radiation dose response of the submandibular gland and minor salivary glands of the oral cavity is less well defined than that of the parotid, but avoidance of these organs in a way that does not compromise target coverage and oncologic outcome is advised [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Xerostomia is the most prevalent late consequence of RT for head and neck cancer and can cause significant symptoms as well as contribute to other complications (eg, dental caries, nutritional issues).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454151\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of contemporary conformal RT techniques to minimize exposure of the salivary glands to radiation is the most important factor in the prevention of permanent salivary gland damage.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    and submandibular salivary gland transfer may have roles in appropriately selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454159\">",
"    <span class=\"h3\">",
"     Highly conformal RT technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of xerostomia depends in large part upon the volume of salivary tissue irradiated. An important benefit of highly conformal RT approaches such as intensity modulated RT (IMRT) is decreased irradiation of the salivary glands and therefore less long-term damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link&amp;anchor=H1493365078#H1493365078\">",
"     \"General principles of radiation therapy for head and neck cancer\", section on 'Intensity-modulated RT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of minimizing radiation to the salivary glands was demonstrated in the PARSPORT trial, in which 94 patients with pharyngeal cancer were randomly assigned to intensity modulated radiation therapy or conventional RT, with a dose of 60 to 65 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/16\">",
"     16",
"    </a>",
"    ]. Grade 2 or worse xerostomia was significantly less common with IMRT at both 12 and 24 months (38 versus 74 percent and 29 versus 83 percent, respectively). There were no significant differences in other toxicities or in tumor control.",
"   </p>",
"   <p>",
"    Another prospective randomized trial also demonstrated statistically significant improvements in observer-related severe xerostomia (39 versus 82 percent), stimulated parotid flow rate, and stimulated whole saliva flow rate among patients with nasopharyngeal cancer who were treated with IMRT rather than two-dimensional RT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/17\">",
"     17",
"    </a>",
"    ]. Unfortunately, patient-reported quality of life did not demonstrate a similar improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454217\">",
"    <span class=\"h3\">",
"     Amifostine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    is an organic thiophosphate that is thought to act by donating a protective thiol group that is a scavenger of free radicals generated in tissues exposed to radiation. Amifostine is the only pharmacologic agent with established efficacy in the prevention of xerostomia, although its role in patient management is uncertain.",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    in the prevention of xerostomia was demonstrated in a trial of 315 patients with head and neck cancer who received definitive or adjuvant postoperative RT (60 to 70 Gy in 1.8 to 2.0 Gy daily fractions) without chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Patients were randomly assigned to intravenous amifostine (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day 30 minutes prior to each radiation dose) or no amifostine. Amifostine reduced the incidence of significant acute xerostomia from 78 to 51 percent, and the incidence of significant chronic xerostomia was found to be reduced at up to 24 months of follow-up. Although concerns have been raised that amifostine might impair the anti-tumor efficacy of treatment, a meta-analysis that included data from 1119 patients on 12 trials, 65 percent of whom had head and neck cancer, found that treatment with amifostine&nbsp;was not associated with an increased risk of death (hazard ratio [HR] for death 0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to recognize that the value of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    in the contemporary management of patients with head and neck cancer is unclear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      &nbsp;is effective at diminishing xerostomia in patients receiving chemoradiotherapy is unclear. Three small randomized trials suggest that amifostine reduces the frequency and severity of xerostomia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/21-23\">",
"       21-23",
"      </a>",
"      ], but one larger trial did not observe a benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The trials demonstrating the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      in preventing xerostomia used older RT techniques. One of the eligibility criteria for the pivotal trial required that a minimum of 75 percent of both salivary glands receive &gt;50 Gy. Whether the benefits with amifostine extend to patients managed with highly conformal, parotid sparing techniques such as IMRT is unclear. (See",
"      <a class=\"local\" href=\"#H722454159\">",
"       'Highly conformal RT technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cost, the inconvenience of daily intravenous infusion, and side effects (eg, hypotension, nausea and vomiting) have limited the widespread use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      . Subcutaneous amifostine has been proposed as a more convenient, less toxic alternative. However, a phase III study that was not double blinded found that subcutaneous administration did not significantly improve patient compliance or efficacy compared with intravenous dosing, and the intravenous route was associated with better salivary outcomes by some measures [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/25\">",
"       25",
"      </a>",
"      ]. Approximately 25 percent of patients discontinue amifostine prior to the completion of their RT because of toxicity from the drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ASCO guidelines recommend that the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    may be considered to reduce the incidence of xerostomia in patients receiving RT only for head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients who may benefit from amifostine are those who are undergoing RT without chemotherapy, are likely to be long-term survivors, are at risk for xerostomia based upon RT fields",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dose, and who are expected to tolerate the added toxicity associated with amifostine administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454352\">",
"    <span class=\"h3\">",
"     Submandibular gland transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical transfer of the submandibular salivary gland to the submental space outside the RT field prior to treatment can be useful to maintain saliva production in carefully selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Five-year follow-up data from an observational series found that this approach prevented radiation-induced xerostomia and improved quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective trial, 120 patients were randomly assigned to salivary gland transfer or to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    during and for three months after RT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/28\">",
"     28",
"    </a>",
"    ]. The trial was stopped at a planned interim analysis because of the superiority of the surgical procedure. At six months, there was a statistically significant increase in both baseline and stimulated salivary gland flow rates and the amount and consistency of saliva, favoring the salivary gland transfer procedure. A secondary analysis of 69 patients found that patients who received the submandibular salivary gland transfer had significant improvement compared with those given pilocarpine in swallowing and multiple parameters of quality of life through one year following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key issues for the use of this technique include the ability to avoid irradiating the submental space without increasing the risk of local recurrence, the identification of a submandibular salivary gland not considered to be at risk for containing cancer cells, and the question of performing a surgical procedure on a patient who is to be managed with RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91978446\">",
"    <span class=\"h3\">",
"     Doxepin rinse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pilot studies using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    rinses suggested that this approach temporarily relieves pain associated with mucositis due to cytotoxic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multicenter, randomized, double-blind, placebo controlled trial, 155 patients reporting at least",
"    <span class=\"nowrap\">",
"     4/10",
"    </span>",
"    pain from oral cavity radiation were given a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    (25 mg in 5 ml water) or a placebo to rinse and spit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/32\">",
"     32",
"    </a>",
"    ]. They subsequently crossed over to the opposite treatment arm. Pain was graded on an analog questionnaire.",
"   </p>",
"   <p>",
"    Preliminary results were presented at the 2012 ASTRO meeting. Treatment with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    rinse significantly decreased pain associated with oral mucositis (mean decrease in self reported pain from 5.5 to 3.5). Despite stinging, burning, and significantly increased mean drowsiness with doxepin, 64 percent of patients elected to continue doxepin rinse after the blinded phase of the trial.",
"   </p>",
"   <p>",
"    Additional confirmation of these results is required before this approach can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454435\">",
"    <span class=\"h3\">",
"     Pilocarpine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     Pilocarpine",
"    </a>",
"    stimulates saliva production from residual salivary gland tissue in patients with established xerostomia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    during RT has been studied as a way to prevent the subsequent development of xerostomia. However, a systematic review of the literature that included 11 randomized trials concluded that oral pilocarpine could be not be recommended to prevent xerostomia in patients receiving RT for head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H674545160\">",
"    <span class=\"h3\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small randomized trials in patients with nasopharyngeal carcinoma suggest that acupuncture can decrease symptoms of xerostomia and improve salivary flow rates. These initial results required confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link&amp;anchor=H29#H29\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Pain control and xerostomia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MUCOSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucositis is a frequent severe complication of RT and chemoradiotherapy. Radiation-induced loss of stem cells in the basal layer interferes with the replacement of cells in the superficial mucosal layers when they are lost through normal physiologic sloughing. The subsequent denuding of the epithelium results in mucositis, which can be painful and interfere with oral intake and nutrition. Chemotherapy can have a similar effect on the mucosa. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454514\">",
"    <span class=\"h2\">",
"     Manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucositis usually becomes clinically evident during the second or third week of RT. Its incidence and severity depend upon the radiation treatment volume, dose fractionation schedule, and the use of induction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concomitant chemotherapy. Some mucositis is experienced by almost all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/36\">",
"     36",
"    </a>",
"    ]. The most effective ways to minimize mucositis are to properly constrain the volumes of normal mucosal tissues within the high dose radiation treatment volumes and to limit concurrent chemotherapy to use in only those patients who are most likely to benefit from this combined modality approach.",
"   </p>",
"   <p>",
"    Severe mucositis is encountered with both contemporary induction regimens and contemporary concurrent chemoradiotherapy regimens. The TAX 324 trial, in which patients were treated with induction chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ) followed by chemoradiotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/37\">",
"     37",
"    </a>",
"    ], reported that approximately 25 percent of patients experienced grade 3 or 4 (severe or life-threatening) mucositis during treatment (",
"    <a class=\"graphic graphic_table graphicRef60597 \" href=\"UTD.htm?15/30/15851\">",
"     table 1",
"    </a>",
"    ). Chemotherapy dose reduction of fluorouracil in subsequent treatment cycles is indicated for grade 4 mucositis or prolonged grade 3 mucositis. The standard arm of RTOG 0129, conventionally fractionated radiotherapy with three cycles of cisplatin, reported that approximately 40 percent of patients experienced grade 3 or 4 mucositis. Only 69 percent of patients were administered the full three cycles secondary to toxicity concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454535\">",
"    <span class=\"h2\">",
"     Management and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucositis is managed symptomatically with scrupulous oral hygiene (including optimization of dentition prior to RT), dietary modification, treatment of superinfections, topical agents, and analgesics.",
"   </p>",
"   <p>",
"    Acidic or spicy foods, sharp foods (eg, chips), caffeine, alcoholic beverages and alcohol-containing mouthwashes should be avoided in patients receiving RT directed at the upper aerodigestive tract. In addition, secondary bacterial, fungal (eg, oral candidiasis), and viral (eg, herpes simplex virus) infections should be treated with appropriate agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link\">",
"     \"Oral toxicity associated with chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite local measures, pain may be significant during and shortly after the course of RT. Long-acting opiates should be used as needed during the treatment period. Long-acting opiates should not be crushed and put in feeding tubes. For patients who cannot swallow oral medication, transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    may provide good pain relief. Short-acting opiates should be used for breakthrough pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454567\">",
"    <span class=\"h3\">",
"     Benzydamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/45/6867?source=see_link\">",
"     Benzydamine",
"    </a>",
"    is a nonsteroidal antiinflammatory agent that is given as an oral rinse and has topical antiinflammatory, analgesic, anesthetic, and antimicrobial activity.",
"   </p>",
"   <p>",
"    In a double-blind trial, 145 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/45/6867?source=see_link\">",
"     benzydamine",
"    </a>",
"    during RT. Patients using benzydamine had a significantly higher rate of freedom from ulceration (33 versus 18 percent) and a delay in the use of systemic analgesics during conventional (&le;50 Gy), but not accelerated fractionation (&ge;2.2 Gy daily) RT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a phase III double-blind placebo-controlled trial failed to confirm these results (NCT00051441); these results have not yet been published.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/45/6867?source=see_link\">",
"     Benzydamine",
"    </a>",
"    is available in Europe but has not been approved by the United States Food and Drug Administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454602\">",
"    <span class=\"h3\">",
"     &ldquo;Miracle&rdquo; mouthwashes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical anesthetics may be combined with an antacid suspension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (for local drying effect) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    &nbsp;in a \"cocktail\", commonly referred to as \"miracle or magic mouthwash\". The specific formulation may vary and may also include steroids and antibiotics; one such cocktail consists of 2 percent viscous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , diphenhydramine, and Maalox. Other \"cocktails\" add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    solution as an anti-inflammatory, or antibiotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    . Care should be advised for patients using rinses containing lidocaine to avoid further trauma to the anesthetized mucosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link\">",
"     \"Oral toxicity associated with chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are many proprietary mouth rinses that are available to alleviate the symptoms of therapy. Care should be exercised in the use of these preparations as the formulations may vary considerably from one institution to another. The administration of multiple agents represents a &ldquo;shotgun&rdquo; approach to management with limited efficacy especially when intensive regimens of chemotherapy and radiotherapy are being used. Data are insufficient to recommend any particular formulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454631\">",
"    <span class=\"h3\">",
"     Palifermin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"     Palifermin",
"    </a>",
"    , also known as keratinocyte growth factor, may accelerate epithelial restoration. Palifermin was evaluated in two trials in patients treated with RT for head and neck cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 198 patients with locally advanced disease were treated with chemoradiotherapy (70 Gy in 35 treatments, combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 22, and 43) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/39\">",
"       39",
"      </a>",
"      ]. Patients were randomly assigned to weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"       palifermin",
"      </a>",
"      or placebo. The incidence of severe mucositis was significantly decreased with palifermin compared with placebo (54 versus 69 percent). The time to onset of severe mucositis and duration of severe mucositis were also improved (47 versus 35 days and 5 versus 26 days, respectively).",
"     </li>",
"     <li>",
"      In a second trial, 186 patients were treated with adjuvant RT (60 or 66 Gy) and concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks) after resection of stage II to IVB head and neck cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/40\">",
"       40",
"      </a>",
"      ]. Patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"       palifermin",
"      </a>",
"      or placebo weekly during chemoradiotherapy. Palifermin significantly decreased the incidence and duration of severe mucositis compared with placebo (51 versus 67 percent and 4.5 versus 22 days); the time to development of mucositis was prolonged (45 versus 32 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    to prevent radiation-induced mucositis remains uncertain. In both trials, there was no decrease in chemotherapy delays or interruptions in radiation due to toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454747\">",
"    <span class=\"h2\">",
"     Laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have observed that pretreatment with laser therapy can decrease oral toxicity due to chemotherapy or RT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    As an example, 221 evaluable patients were randomly assigned to daily laser or sham treatments during a six week course of chemoradiotherapy for primary oropharyngeal or oral cavity cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/45\">",
"     45",
"    </a>",
"    ]. Chemoradiotherapy consisted of 66 Gy of RT in 33 fractions, combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    on days 1, 22, and 43. Low level laser therapy was given daily prior to RT five times per week for 45 days. Patients and assessors were blinded to treatment assignment. Laser therapy significantly decreased the incidence of grade 3 or 4 mucositis at the end of chemoradiotherapy (23 versus 69 percent). Laser therapy also decreased average pain scores using a visual analog scale, analgesic usage, and the need for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Although these results are encouraging, the mechanism of action unclear and the potential interaction with RT needs to be studied. The prophylactic use of laser therapy to prevent RT-induced mucositis cannot be recommended until its safety and efficacy are verified in a multi-institutional trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722454754\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other agents have been evaluated to a much more limited extent for their role in the management or prevention of mucositis, but currently available evidence does not support their use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       Sucralfate",
"      </a>",
"      &nbsp;&ndash;&nbsp;Evidence from a systematic review of the literature and one contemporary placebo-controlled trial indicates that prophylactic mouth washing with sucralfate&nbsp;during radiation therapy does not reduce the degree of mucositis and is not indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Antimicrobial lozenges &ndash;",
"      </strong>",
"      Infection has been postulated to play a role in the development of mucositis. However, oral lozenges containing combinations of antibacterial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antifungal agents failed to decrease the incidence or severity of mucositis in patients receiving radiation therapy in phase III clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Iseganan &ndash;",
"      </strong>",
"      Iseganan is a synthetic peptide with broad spectrum antimicrobial activity that is available in an oral solution. Iseganan was tested in a large, multi-institutional phase III trial but failed to meaningfully affect the pathogenesis of radiation-induced mucositis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"       Amifostine",
"      </a>",
"      &nbsp;&ndash; Amifostine decreases the incidence of xerostomia in patients receiving radiation therapy for head and neck cancer. In the trial establishing the activity of amifostine for the prevention of xerostomia, there was no evidence that treatment prevented mucositis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/18\">",
"       18",
"      </a>",
"      ]. Guidelines from ASCO do not recommend amifostine to prevent RT-related mucositis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H722454217\">",
"       'Amifostine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Phenylbutyrate",
"      </strong>",
"      &ndash; Phenylbutyrate mouthwash was compared with a placebo mouthwash in a 36 patient phase II randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/50\">",
"       50",
"      </a>",
"      ]. Results suggested that phenylbutyrate mouthwashes, initiated at the earliest appearance of toxicity, significantly decreased the severity of oral mucositis.",
"     </li>",
"     <li>",
"      <strong>",
"       Glutamine",
"      </strong>",
"      &nbsp;&ndash; Pilot trials using various oral or intravenous glutamine preparations have suggested that this agent can decrease the incidence or severity of mucositis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. These results require confirmation in larger trials. Current guidelines recommend that systemic glutamine not be used for the prevention of mucositis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Colony stimulating factors",
"      </strong>",
"      &ndash; Both granulocyte-macrophage colony-stimulating factor (GM-CSF) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) have been studied to reduce the incidence and severity of mucositis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/53-58\">",
"       53-58",
"      </a>",
"      ]. However, the evidence is insufficient to support their use, particularly since one large trial has suggested that there is significantly worse locoregional control and survival in patients with advanced head and neck cancer treated with hyperfractionated radiotherapy or chemoradiotherapy plus G-CSF compared to those receiving the same treatments without G-CSF [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/57/17300?source=see_link\">",
"       Zinc sulfate",
"      </a>",
"      &nbsp;&ndash;&nbsp;Preliminary trials suggest that oral zinc sulfate&nbsp;may be beneficial in treating and preventing mucositis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/60-62\">",
"       60-62",
"      </a>",
"      ]. These results require confirmation.",
"     </li>",
"     <li>",
"      <strong>",
"       Manuka honey",
"      </strong>",
"      &ndash; A preliminary trial suggested that administration of manuka honey multiple times daily limited radiation mucositis in patients received chemoradiotherapy, as compared to a control group that received chemoradiotherapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/63\">",
"       63",
"      </a>",
"      ]. A subsequent placebo-controlled trial failed to demonstrate a similar benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722455156\">",
"    <span class=\"h1\">",
"     DENTAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental status has a significant effect on posttreatment quality of life among patients with head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Patients with head and neck cancer often have poor preexisting dentition and dental health, which may result in increased risks of complications from their cancer treatment, including osteoradionecrosis and infection in particular.",
"   </p>",
"   <p>",
"    All patients who will be treated with RT for head and neck cancer should undergo a comprehensive dental evaluation prior to treatment. The edentulous patient should be evaluated for retained root tips, alveolar hyperplasia, maintenance of oral hygiene, and assessment for prosthodontics.",
"   </p>",
"   <p>",
"    Indications for tooth extraction prior to RT are compromised teeth in an area that is expected to receive a dose of at least 50 Gy or a tooth that is out of the radiation treatment volume, but has a hopeless prognosis or is symptomatic. Extraction of healthy teeth does not appear to prevent the development of osteoradionecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All indicated extractions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    restorative work should be completed prior to RT. A delay of approximately two weeks is ideal between extractions and the beginning of RT to permit proper healing. If the extracted teeth are outside of the treatment volumes, treatment may be initiated sooner. An adequate alveoloplasty should be performed to make the",
"    <span class=\"nowrap\">",
"     mandible/maxilla",
"    </span>",
"    &ldquo;denture ready&rdquo;. Primary closure is preferred if possible. Postponing needed dental extractions of teeth that will be within the treatment volume until after treatment is associated with an increased risk of non-healing and osteoradionecrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decrease in saliva and changes in its chemical composition induced by cancer treatment can alter the microbial flora of the mouth and increase the risk of subsequent dental caries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822348#H3822348\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Salivary gland damage and xerostomia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the long-term maintenance of oral hygiene should be initiated in conjunction with cancer treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of fluoride has been shown to decrease the incidence of caries in patients who have received prior RT. There is no evidence to support the use of one fluoride delivery system over another. Patients should continue to use fluoride daily for the remainder of their lives.",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      rinse reduces plaque scores, although this can result in tooth staining, increased calculus formation, or altered sense of taste.",
"     </li>",
"     <li>",
"      Long-term follow-up by an experienced dentist should be provided. Clinical circumstances may require routine visits three to four times per year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722455164\">",
"    <span class=\"h1\">",
"     RADIATION DERMATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation dermatitis in the treatment field is common during radiation therapy. The spectrum of injury ranges from hyperpigmentation and dry desquamation of the epithelial layers to moist desquamation and skin necrosis.",
"   </p>",
"   <p>",
"    Damage to the skin can be aggravated by chemotherapeutic agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    . Concurrent treatment with cetuximab may be particularly important as a cause of severe radiation dermatitis compared with cisplatin. In a trial in which 424 patients with locoregionally advanced head and neck cancer were randomly assigned to RT with or without concurrent weekly cetuximab, an acneiform rash was significantly more common with cetuximab than with RT alone (84 versus 10 percent), and a severe skin reaction was also significantly more common (35 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H281027372#H281027372\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Epidermal growth factor inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9322?source=see_link\">",
"     \"Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to initiating RT, patients should be instructed about appropriate skin care and avoidance of exposure to potential chemical irritants. They should also limit direct sun (UV) and wind exposure.",
"   </p>",
"   <p>",
"    A number of commercially available skin care products can be used during RT to provide lubrication and protect the skin. These include aloe vera-based gels and water-based lotions. Although such preparations may provide symptom palliation, none promotes or accelerates healing of radiation-induced dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722455196\">",
"    <span class=\"h1\">",
"     DYSGEUSIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysgeusia is defined as abnormal or impaired sense of taste; the sense of taste may also be affected by impaired olfaction. An altered sense of taste",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    smell may contribute to nutritional difficulties and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both chemotherapy and RT may impair the sense of taste by their effects on the receptors in the tongue and nasal epithelium. Other factors that may contribute to an altered sense of taste include a bitter taste from chemotherapy drugs, poor oral hygiene, infection, and mucositis.",
"   </p>",
"   <p>",
"    In a systematic review of the literature, patients treated with chemotherapy only, RT only, and chemotherapy plus RT had dysgeusia in 56, 67, and 76 percent of cases respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/69\">",
"     69",
"    </a>",
"    ]. The incidence is probably significantly higher in patients receiving a full course of RT or chemoradiotherapy, with an onset of impairment during the first two weeks. The sense of taste generally improves after completion of therapy, with return to normal or near normal levels by one year.",
"   </p>",
"   <p>",
"    Pharmacologic strategies to prevent or improve the sense of taste using zinc supplementation or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    have not shown consistent benefit, and these approaches are not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/69\">",
"     69",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Dietary counseling may be of value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722455241\">",
"    <span class=\"h1\">",
"     OROFACIAL PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orofacial pain is frequent in patients with head and neck cancer. A systematic review of the literature that included over 3000 patients with squamous cell carcinoma of the head and neck found that pain was present in approximately 50 percent of patients prior to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/70\">",
"     70",
"    </a>",
"    ]. During treatment, about 80 percent of patients complained of pain. Although treatment resulted in some improvement, 36 percent of patients still had such symptoms six months after treatment.",
"   </p>",
"   <p>",
"    The orofacial pain in these patients appears to be multifactorial. Mucositis, which is frequent during RT with or without concurrent chemotherapy, contributes to some of the observed worsening of pain during treatment. Other factors that can contribute to orofacial pain include damage from the cancer itself, inflammation, infection, and scarring from surgery or other treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skillful pain management often determines whether or not a feeding tube is required and whether or not treatment can be completed in a timely manner. The general principles of cancer pain management, including the use of both narcotics and coanalgesics, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'General principles of pain management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16450708\">",
"    <span class=\"h1\">",
"     TRISMUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trismus is a condition characterized by limited jaw opening that is generally caused by a combination of spasm, fibrosis, and contraction of the muscles responsible for movement at the temporomandibular joint. Limited jaw opening during therapy is typically secondary to mucositis and pain. For that reason, passive motion devices are generally not used during radiotherapy. By contrast, passive motion devices can generally be instituted early in the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/1/22554/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H707302548\">",
"    <span class=\"h1\">",
"     MALNUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xerostomia, mucositis, dental issues, abnormalities in taste and smell, and orofacial pain can all contribute to difficulties in maintaining adequate nutrition during and after treatment. The approach to nutritional support in these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=see_link&amp;anchor=H14#H14\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'Head and neck cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616616079\">",
"    <span class=\"h1\">",
"     REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional rehabilitation is an important component of patient management and can be essential for an optimal outcome following treatment. These issues are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16231?source=see_link\">",
"       \"Alaryngeal speech rehabilitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=see_link\">",
"       \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/59/11186?source=see_link\">",
"       \"Patient information: Mouth sores from cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722455285\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers of the upper aerodigestive tract are in close proximity to and often emanate from organs that have an important impact on a patient&rsquo;s quality of life (eg, tongue, larynx, mandible, pharynx). This involvement with cancer and its subsequent eradication can cause a wide spectrum of toxicities, including impairment in the ability to breathe, communicate, and maintain an adequate oral intake. The treatment of head and neck cancers is complex, and best handled by a coordinated team involving surgeons, radiation oncologists, medical oncologists, dentists, oral surgeons, speech pathologists,",
"    <span class=\"nowrap\">",
"     physical/occupational",
"    </span>",
"    therapists, nutritionists, and skilled nurses. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Spectrum of issues'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       General measures",
"      </strong>",
"      &ndash; Optimal management should include the avoidance of treatment breaks whenever possible. Supportive measures should be instituted early in an attempt to avoid breaks. In addition, smoking cessation likely improves oncologic outcome and reduces treatment-related side effects; it should be strongly encouraged. (See",
"      <a class=\"local\" href=\"#H1057183973\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Xerostomia",
"      </strong>",
"      &ndash; The most proven means to minimize salivary gland toxicity is with highly conformal radiation therapy techniques. Planning of radiation therapy fields that avoids the oral cavity and contralateral submandibular gland likely improves patient quality of life in instances where it is oncologically safe. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      is not standard. Although amifostine has been shown to decrease salivary gland toxicity with older radiation therapy techniques, there are no analyses demonstrating a benefit of amifostine in the setting of contemporary, highly conformal radiation therapy techniques. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Salivary gland damage and xerostomia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Mucositis",
"      </strong>",
"      &ndash; Mucositis to some degree is unavoidable. Dietary modification (avoidance of spicy and dry foods), narcotic pain medication, repeated exogenous lubrication, and oral hygiene are all recommended. There are many innovative means to limit this symptom. Data are insufficient to make a recommendation of newer therapies. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mucositis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Dental issues",
"      </strong>",
"      &ndash; Poor oral hygiene should be addressed prior to the initiation of RT. Every patient should see a dentist prior to initiation of therapy and should be using fluoride treatments to preserve any remaining teeth. Dental problems after radiotherapy require special attention. Long-term maintenance of oral hygiene should be initiated in conjunction with cancer treatment. (See",
"      <a class=\"local\" href=\"#H722455156\">",
"       'Dental issues'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      <strong>",
"       Nutritional support",
"      </strong>",
"      &ndash; The various acute complications of head and neck cancer and its treatment can all contribute to severely impaired nutrition in this patient population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=see_link&amp;anchor=H14#H14\">",
"       \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'Head and neck cancer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Other side effects",
"      </strong>",
"      &ndash; Radiation dermatitis, dysgeusia, and orofacial pain are common acute effects and should be managed expectantly. (See",
"      <a class=\"local\" href=\"#H722455196\">",
"       'Dysgeusia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H722455164\">",
"       'Radiation dermatitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H722455241\">",
"       'Orofacial pain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/1\">",
"      Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/2\">",
"      Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15:3149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/3\">",
"      Ang KK, et AL. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (abstract #5500). J Clin Oncol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/4\">",
"      Rugg T, Saunders MI, Dische S. Smoking and mucosal reactions to radiotherapy. Br J Radiol 1990; 63:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/5\">",
"      Browman GP, Wong G, Hodson I, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993; 328:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/6\">",
"      Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/7\">",
"      Burlage FR, Coppes RP, Meertens H, et al. Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiother Oncol 2001; 61:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/8\">",
"      Avila JL, Grundmann O, Burd R, Limesand KH. Radiation-induced salivary gland dysfunction results from p53-dependent apoptosis. Int J Radiat Oncol Biol Phys 2009; 73:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/9\">",
"      Abok K, Brunk U, Jung B, Ericsson J. Morphologic and histochemical studies on the differing radiosensitivity of ductular and acinar cells of the rat submandibular gland. Virchows Arch B Cell Pathol Incl Mol Pathol 1984; 45:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/10\">",
"      Nagler R, Marmary Y, Fox PC, et al. Irradiation-induced damage to the salivary glands: the role of redox-active iron and copper. Radiat Res 1997; 147:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/11\">",
"      Deasy JO, Moiseenko V, Marks L, et al. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys 2010; 76:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/12\">",
"      Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001; 49:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/13\">",
"      Blanco AI, Chao KS, El Naqa I, et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/14\">",
"      Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/15\">",
"      Murdoch-Kinch CA, Kim HM, Vineberg KA, et al. Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/16\">",
"      Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/17\">",
"      Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25:4873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/18\">",
"      Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18:3339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/19\">",
"      Wasserman TH, Brizel DM, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 2005; 63:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/20\">",
"      Bourhis J, Blanchard P, Maillard E, et al. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. J Clin Oncol 2011; 29:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/21\">",
"      Antonadou D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 52:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/22\">",
"      B&uuml;ntzel J, K&uuml;ttner K, Fr&ouml;hlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 1998; 9:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/23\">",
"      Vacha P, Fehlauer F, Mahlmann B, et al. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 2003; 179:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/24\">",
"      Buentzel J, Micke O, Adamietz IA, et al. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 2006; 64:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/25\">",
"      Bardet E, Martin L, Calais G, et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial. J Clin Oncol 2011; 29:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/26\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/27\">",
"      Liu XK, Su Y, Jha N, et al. Submandibular salivary gland transfer for the prevention of radiation-induced xerostomia in patients with nasopharyngeal carcinoma: 5-Year outcomes. Head Neck 2011; 33:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/28\">",
"      Jha N, Seikaly H, Harris J, et al. Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia. Head Neck 2009; 31:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/29\">",
"      Jha N, Harris J, Seikaly H, et al. A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244). Int J Radiat Oncol Biol Phys 2012; 84:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/30\">",
"      Rieger JM, Jha N, Lam Tang JA, et al. Functional outcomes related to the prevention of radiation-induced xerostomia: oral pilocarpine versus submandibular salivary gland transfer. Head Neck 2012; 34:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/31\">",
"      Epstein JB, Epstein JD, Epstein MS, et al. Oral doxepin rinse: the analgesic effect and duration of pain reduction in patients with oral mucositis due to cancer therapy. Anesth Analg 2006; 103:465.",
"     </a>",
"    </li>",
"    <li>",
"     Miller RC, Leenstra J, Qun R, et al. A Phase III, Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy (abstract LBA2). American Society for Radiation Oncology 2012 Annual meeting.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/33\">",
"      Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 2010; 18:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/34\">",
"      Meng Z, Garcia MK, Hu C, et al. Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Cancer 2012; 118:3337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/35\">",
"      Meng Z, Kay Garcia M, Hu C, et al. Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Eur J Cancer 2012; 48:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/36\">",
"      Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2007; 68:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/37\">",
"      Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/38\">",
"      Epstein JB, Silverman S Jr, Paggiarino DA, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001; 92:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/39\">",
"      Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol 2011; 29:2808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/40\">",
"      Henke M, Alfonsi M, Foa P, et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol 2011; 29:2815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/41\">",
"      Bensadoun RJ, Franquin JC, Ciais G, et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 1999; 7:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/42\">",
"      Arun Maiya G, Sagar MS, Fernandes D. Effect of low level helium-neon (He-Ne) laser therapy in the prevention &amp; treatment of radiation induced mucositis in head &amp; neck cancer patients. Indian J Med Res 2006; 124:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/43\">",
"      Gouv&ecirc;a de Lima A, Villar RC, de Castro G Jr, et al. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study. Int J Radiat Oncol Biol Phys 2012; 82:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/44\">",
"      Bensadoun RJ, Nair RG. Low-level laser therapy in the prevention and treatment of cancer therapy-induced mucositis: 2012 state of the art based on literature review and meta-analysis. Curr Opin Oncol 2012; 24:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/45\">",
"      Gautam AP, Fernandes DJ, Vidyasagar MS, et al. Low level laser therapy for concurrent chemoradiotherapy induced oral mucositis in head and neck cancer patients - a triple blinded randomized controlled trial. Radiother Oncol 2012; 104:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/46\">",
"      Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/47\">",
"      Stokman MA, Spijkervet FK, Burlage FR, et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer 2003; 88:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/48\">",
"      El-Sayed S, Nabid A, Shelley W, et al. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 2002; 20:3956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/49\">",
"      Trotti A, Garden A, Warde P, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 2004; 58:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/50\">",
"      Yen SH, Wang LW, Lin YH, et al. Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 2012; 82:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/51\">",
"      Huang EY, Leung SW, Wang CJ, et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 2000; 46:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/52\">",
"      Cerchietti LC, Navigante AH, Lutteral MA, et al. Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006; 65:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/53\">",
"      Wagner W, Alfrink M, Haus U, Matt J. Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer. Anticancer Res 1999; 19:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/54\">",
"      Nicolatou O, Sotiropoulou-Lontou A, Skarlatos J, et al. A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: a preliminary report. Int J Radiat Oncol Biol Phys 1998; 42:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/55\">",
"      Ryu JK, Swann S, LeVeque F, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys 2007; 67:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/56\">",
"      Makkonen TA, Minn H, Jekunen A, et al. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. Int J Radiat Oncol Biol Phys 2000; 46:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/57\">",
"      Sprinzl GM, Galvan O, de Vries A, et al. Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer 2001; 37:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/58\">",
"      Su YB, Vickers AJ, Zelefsky MJ, et al. Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Cancer J 2006; 12:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/59\">",
"      Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/60\">",
"      Ertekin MV, Ko&ccedil; M, Karslioglu I, Sezen O. Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int J Radiat Oncol Biol Phys 2004; 58:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/61\">",
"      Lin LC, Que J, Lin KL, et al. Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study. Int J Radiat Oncol Biol Phys 2008; 70:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/62\">",
"      Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. Int J Radiat Oncol Biol Phys 2006; 65:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/63\">",
"      Rashad UM, Al-Gezawy SM, El-Gezawy E, Azzaz AN. Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer. J Laryngol Otol 2009; 123:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/64\">",
"      Bardy J, Molassiotis A, Ryder WD, et al. A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Br J Oral Maxillofac Surg 2012; 50:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/65\">",
"      Duke RL, Campbell BH, Indresano AT, et al. Dental status and quality of life in long-term head and neck cancer survivors. Laryngoscope 2005; 115:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/66\">",
"      Hong CH, Nape&ntilde;as JJ, Hodgson BD, et al. A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 2010; 18:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/67\">",
"      Chang DT, Sandow PR, Morris CG, et al. Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible? Head Neck 2007; 29:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/68\">",
"      Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/69\">",
"      Hovan AJ, Williams PM, Stevenson-Moore P, et al. A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 2010; 18:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/70\">",
"      Epstein JB, Hong C, Logan RM, et al. A systematic review of orofacial pain in patients receiving cancer therapy. Support Care Cancer 2010; 18:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/1/22554/abstract/71\">",
"      Cohen EG, Deschler DG, Walsh K, Hayden RE. Early use of a mechanical stretching device to improve mandibular mobility after composite resection: a pilot study. Arch Phys Med Rehabil 2005; 86:1416.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3408 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-05FC37673D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22554=[""].join("\n");
var outline_f22_1_22554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H722455285\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1057183973\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Spectrum of issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H707302341\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SALIVARY GLAND DAMAGE AND XEROSTOMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H722454123\">",
"      Acute injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H722454151\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H722454159\">",
"      - Highly conformal RT technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H722454217\">",
"      - Amifostine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H722454352\">",
"      - Submandibular gland transfer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91978446\">",
"      - Doxepin rinse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H722454435\">",
"      - Pilocarpine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H674545160\">",
"      - Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MUCOSITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H722454514\">",
"      Manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H722454535\">",
"      Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H722454567\">",
"      - Benzydamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H722454602\">",
"      - &ldquo;Miracle&rdquo; mouthwashes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H722454631\">",
"      - Palifermin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H722454747\">",
"      Laser therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H722454754\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H722455156\">",
"      DENTAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H722455164\">",
"      RADIATION DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H722455196\">",
"      DYSGEUSIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H722455241\">",
"      OROFACIAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16450708\">",
"      TRISMUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H707302548\">",
"      MALNUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H616616079\">",
"      REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H722455285\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3408\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3408|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/30/15851\" title=\"table 1\">",
"      Grading severity mucositis according to the NCI CTCAE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9322?source=related_link\">",
"      Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16231?source=related_link\">",
"      Alaryngeal speech rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/59/11186?source=related_link\">",
"      Patient information: Mouth sores from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_1_22555="Scleroderma fibroblasts";
var content_f22_1_22555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Properties of scleroderma dermal fibroblasts in tissue culture",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Collagen I and III mRNA and protein production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteoglycan synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibronectin synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolyl and lysyl hydroxylase enzyme activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PDGF receptor expression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Production of IL-1 and IL-6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum independent proliferation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surface expression and shedding of ICAM-1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Collagenase secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suceptibility to anti-Fas induced apoptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reduced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Collagen I mRNA downregulation in collagen gel matrix culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Collagenase production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proliferative response to recombinant EGF, endothelin-1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22555=[""].join("\n");
var outline_f22_1_22555=null;
var title_f22_1_22556="Depression in AD";
var content_f22_1_22556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Depression in Alzheimer-type dementia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"1\" rowspan=\"1\">",
"        A. Three or more of the following",
"symptoms, present during the same two-week period, and representing a",
"change from a previous level of functioning. Either item-one or",
"item-two must be included:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Clinically significant depressed mood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Decreased positive affect or pleasure in response to social contacts and usual activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Social isolation or withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Disturbed appetite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Disturbed sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6. Psychomotor retardation or agitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7. Irritability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        8. Fatigue or loss of energy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        9. Feelings of worthlessness, hopelessness, or inappropriate guilt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        10. Recurrent thoughts of death or suicidal ideation, plan, or any attempt&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Meets criteria for Alzheimer-type dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        C. Depressive symptoms cause clinically significant distress or disruption in function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Symptoms do not occur exclusively during an episode of delirium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        E. Symptoms are not due to a direct physiological effect from a substance (medication or drug of abuse)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        F. Symptoms are not better accounted for by another condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Specify if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Co-occuring onset: onset antedates or co-occurs with AD symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Post-AD onset: onset occurs after AD diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Specify if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"1\">",
"        With psychosis of AD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        With other significant behaviorial signs or symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        With past history of mood disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22556=[""].join("\n");
var outline_f22_1_22556=null;
var title_f22_1_22557="Reservoir cannulas and SaO2";
var content_f22_1_22557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Performance of the reservoir cannulas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 220px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The reservoir cannulas (Oxymizer and Pendant) set at 0.5 L/min will achieve an SaO",
"    <sub>",
"     2",
"    </sub>",
"    equivalent to continuous flow at 2 L/min - an efficacy of 4:1. Similarly, 2 L/min will achieve an SaO",
"    <sub>",
"     2",
"    </sub>",
"    equivalent to continuous flow at 4 L/min - an efficacy of 2:1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tiep BL. Reservoir cannulas. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Futura Publishing, Mt Kisco, New York, 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22557=[""].join("\n");
var outline_f22_1_22557=null;
var title_f22_1_22558="Exercise intensity and duration and reduction in mortality";
var content_f22_1_22558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Exercise intensity and duration and reduction in mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 344px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    % : percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Wen CP, Wai JPM, Tsai MK, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: A prospective cohort study. Lancet 2011; 378:1244. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22558=[""].join("\n");
var outline_f22_1_22558=null;
var title_f22_1_22559="Aspiration subtalar joint";
var content_f22_1_22559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspiration from subtalar joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unilateral ankle effusions can be crystal-induced \"cluster attacks\" in which several anatomically adjacent joints are involved. These attacks can sometimes be made to yield fluid by aspirating the subtalar joint, one finger breadth below the prominence of the lateral malleolus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_1_22559=[""].join("\n");
var outline_f22_1_22559=null;
